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2. Introduction 
2.1 The maintenance of the Ca2+ homeostasis 
Ca2+ is an essential component of living organisms. In vertebrates calcium salts are the 
building blocks of the bones and teeth while ionized serum calcium is a first messenger in 
the blood, which by acting through the calcium-sensing receptor regulates diverse 
physiological processes as bone remodeling or intestinal water absorption [1].  
Furthermore, calcium is an important second messenger within the cells where it takes 
part in the regulation of vital processes from proliferation to cell death [2]. Intracellular 
Ca2+ signals show high spatiotemporal versatility and this way they are capable to 
regulate distinct intracellular processes [3]. While in synapses Ca2+ signal triggers 
exocytosis in milliseconds, its signaling effect can also last for hours driving cell division 
or apoptosis. The intracellular Ca2+ level is regulated by a cell type specific toolkit. The 
composition of the toolkit changes adaptively depending on the fate of the cell being 
that either differentiation or cell death. This remodeling of the Ca2+ handling system 
makes possible for the cell to cope with different circumstances, but its abnormal 
changes contribute to the formation of several diseases such as Alzheimer disease or 
cancer.  
In resting state the intracellular Ca2+ concentration is between 100-200 nM, while in the 
outer space it is around 1 mM. Most of the cytosolic Ca2+ is bound to membrane surfaces 
or to calcium-binding proteins. The maintenance of the low intracellular Ca2+ 
concentration – that requires a lot of energy - is necessary to avoid the formation of 
calcium hydroxide phosphates in the cytosol. The steep Ca2+ gradient contributes to the 
strong electrochemical gradient across the plasma membrane that also drives Ca2+ 
uptake [4].   
Ca2+ works as a second messenger through the formation of calcium transients. Berridge 
et al. divides the processes, which create Ca2+ signals, into two groups; the “ON 
processes” contribute to the increase, while the “OFF processes” to the decrease of the 
intracellular Ca2+ concentration [5]. Ca2+ can enter the cytosol through plasma membrane 
channels from outside of the cell or from intracellular stores, and then it is actively 
removed by Ca2+ pumps and/or exchangers, and is also buffered by Ca2+ binding 
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proteins/acidic lipids. Given that there are many different isoforms generated from each 
of these proteins of the Ca2+ signaling toolkit, the characteristics of the Ca2+ signal can be 
vastly versatile from small single spikes to high frequency oscillations. Depending on the 
spatiotemporal features of the Ca2+ signal distinct Ca2+ - dependent effectors become 
activated influencing basic cellular processes like proliferation, cell migration, exocytosis 
or apoptosis (Figure 1.).  
 
 
Figure 1. The Ca2+ signal is generated by the concerted actions of the “on” and “off” 
reactions. The Ca2+ molecules can enter the cytosol from the extracellular space or they can 
be released from the internal stores through Ca2+ channels. The excess Ca2+ is removed by 
Ca2+ pumps, exchangers and buffers [6].  
2.1.1 Ca2+ increase reactions 
2.1.1.1. Ca2+ release from the internal stores 
Ca2+ is stored in distinct compartments within the cells, primarily in the endoplasmic 
reticulum / sarcoplasmic reticulum (ER/SR) and in the mitochondria. After stimulus Ca2+ is 
quickly released from the ER through the activation of membrane receptors IP3Rs (inositol 
1,4,5-trisphosphate receptor) [7], and from the SR by ryanodine receptors (RYR) [8]. IP3Rs are 
receptor channel molecules, which are activated by the second messenger IP3 and by Ca
2+ 
itself. IP3 is generated from inositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC), which 
is coupled to several cell surface receptors, such as G-protein-coupled receptors (GPCRs) or 
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receptor tyrosine kinase-linked receptors (RTKRs). Ryanodine receptors are mostly found in 
excitable cells. They are directly activated by L-type Ca2+ channels in the striated muscle, 
while in other cell types their opening is initiated by the increasing cytoplasmic Ca2+ 
concentration. This phenomenon is called Ca2+ induced Ca2+ release (CICR). IP3Rs are also 
activated by Ca2+ until its concentration reaches ~ 300 nM in the cytosol, which in turn 
inhibits Ca2+ release through the receptor [6].  
The mitochondria are also sensitive to the rise of the cytosolic Ca2+ concentration that takes 
up Ca2+ by the mitochondrial calcium uniporter (MCU). Elevated Ca2+ concentration within 
the mitochondria induces ATP production through the activation of the Ca2+ sensitive 
dehydrogenases, which provides energy for the regulation of the Ca2+ transients and the 
following cell responses. An elevated Ca2+ concentration in the mitochondria also induces 
increased production of reactive oxygen species (ROS). During the decay phase of 
intracellular Ca2+ signal Ca2+ is removed from the mitochondria by Na+/Ca2+ and H+/ Ca2+ 
exchangers. In case of a Ca2+ overload the mitochondrial permeability transition pores (MTP) 
open through which cytochrome-c is released that in turn triggers apoptosome formation 
and ultimately apoptosis in the cell [9]. 
Calcium is also stored in the Golgi apparatus and a Ca2+ efflux – independent of the ER Ca2+ 
store – was shown through the Golgi IP3Rs. However, the exact mechanism of the Golgi Ca
2+ 
release process is still unclear. Calcium ions are also stored in the cytoplasm attached to 
Ca2+-binding proteins such as calretinin and parvalbumins [10]. The high amount of Ca2+ 
stored in the ER and the mitochondria are also bound to other Ca2+-binding proteins within 
the organelles, for example to calreticulin in the ER, calsequestrin in the SER.  
2.1.1.2. Plasma membrane Ca2+ channels 
Ca2+ influx from the outer space is driven by the electrochemical gradient between the two 
sides of the plasma membrane. There are many different types of plasma membrane Ca2+ 
channels that can be divided into three groups based on their gating characteristics [5]. 
Voltage gated Ca2+ channels are found in excitable cells and their activation requires only 
milliseconds, initiating cellular responses such as synaptic vesicle fusion or muscle 
contraction. Another group of channels are gated by the binding of a specific ligand. The 
receptor-operated channels bind a ligand from the external space, while second messenger-
operated channels react to ligands from the internal space. An example for the former is the 
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glutamate binding NMDA (N-methyl-D-aspartate) receptors [11], for the latter the 
arachidonic acid sensitive Ca2+ channels [12]. The third large group of channels is activated 
by the depletion of the internal Ca2+ stores, these are the store operated Ca2+ channels 
(SOCs).  
Store operated Ca2+ entry (SOCE) is noticeable in almost all non-excitable cell types, and it 
often controls Ca2+ mediated processes in excitable cells, as well. SOCE is generated primarily 
by two families of proteins [13]. STIM proteins (stromal interacting molecule) localize to the 
ER membrane having a Ca2+-binding EF-hand domain on their ER lumen facing N-terminus. 
When the Ca2+ concentration in the lumen of the ER decreases, the Ca2+ ions dissociate from 
this domain and after oligomerization the STIM molecules relocate to ER-plasma membrane 
junctions. Here they activate the pore formation of the Orai protein family (Orai1-3) by 
direct binding allowing Ca2+ entry across the plasma membrane from the extracellular space. 
[13]. As a result, after the decrease of the ER lumen Ca2+ level, the so-called calcium release 
activated calcium (CRAC) current is measurable through the plasma membrane. 
In non-excitable cells Ca2+ store depletion most often is a consequence of IP3R activation. IP3 
is produced after cell surface receptor stimulation by many different stimuli, such as 
hormones, growth factors or ATP. SOCE is an example when the main sources of Ca2+ - 
internal and external - are combined and contribute to the rise of the Ca2+ signals [14]. 
2.1.2 Ca2+ decrease reactions 
After Ca2+ level increase, the intracellular Ca2+ concentration needs to be lowered to its basal 
level by the concerted action of the Na+/Ca2+ exchangers (NCX), the plasma membrane Ca2+ 
ATPases (PMCA), the sarco/endoplasmic reticulum Ca2+ ATPases (SERCA) and the 
mitochondrial uniporters. NCX becomes activated by micromolar Ca2+ concentration, 
however, it can remove quickly high amount of Ca2+ from the cytosol by virtue of its high 
transport capacity. It transports one Ca2+ ion at the expense of three sodium ions entering 
the cytoplasm using the transmembrane sodium gradient. It is mostly found in excitable 
cells, especially in cardiac and skeletal muscle and in the nervous system [15].  
PMCA and SERCA pumps are low capacity but high affinity transporters being able to restore 
the very low 100 nM resting cytosolic Ca2+ concentration. They use the energy of ATP 
molecules to pump Ca2+ ions against their concentration gradient towards the outer space or 
into the ER lumen. Another Ca2+ pump, the secretory-pathway Ca2+ ATPase (SPCA) transports 
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Ca2+ into the Golgi compartments with high affinity. It does not only contribute to the uptake 
of excess Ca2+ from the cytosol, but it is also able to transport Mn2+ ions. Both Ca2+ and Mn2+ 
molecules are necessary for the basic function of the secretory pathway such as protein 
synthesis, folding or trafficking. Mn2+ is also a cofactor in number of enzymes and its removal 
from the cytosol by SPCA prevents its accumulation to toxic levels [16]. 
Mitochondrial uniporters (MCUs) use the mitochondrial membrane potential as an energy 
source for ion transport. The uniporter is active when Ca2+ concentration is high. This can 
happen when the Ca2+ level in the entire cytosol is strongly increased, or only locally when 
the ER and mitochondria are in close proximity and Ca2+ released by the IP3R or RYR directly 
activate mitochondrial Ca2+ uptake [17]. Fine tuning of intracellular Ca2+ signals is 
accomplished by the regulation of expression and activity of the numerous isoforms and 
splice variants of this Ca2+ toolkit. 
 
2.2. Ca2+ transport ATPases 
In mammals three types of Ca2+ ATPase are known: PMCAs, SPCAs and SERCAs. All of them 
belong to the P-type ATPases as during their enzymatic cycle a phosphorylated aspartate 
intermediate is generated. They use ATP to translocate ions against their electrochemical 
gradient and they all can be inhibited by the transition state analogue orthovanadate. P-type 
ATPases have 10 transmembrane domains including strongly conserved regions in the 
cytoplasmic side between the second and third, and the fourth and fifth domains [18].  
2.2.1. Sarco/endoplasmic reticulum Ca2+- transport ATPase (SERCA) 
There are three SERCA proteins (SERCA1-3) coded by 3 different genes (ATP2A1-3). Their 
main role is to refill the Ca2+ stores and restore the basic Ca2+ concentration of the cytosol 
after transients. They pump 2 Ca2+ ions into the ER/SR by hydrolyzing one ATP molecule [19]. 
Among the Ca2+ transport ATPases only the SERCA1 protein was successfully crystalized [20]. 
Based on its crystal structure SERCA proteins have four large domains: the M-domain 
(membrane domain), which contains the 10 transmembrane helices, and the cytosolic A 
(actuator)-, N (nucleotide binding)- and P (phosphorylation)-domains. ATP binds to the N-
domain, while the phosphorylated aspartate residue is located in the P-domain. The A-
domain coordinates the movement of the N- and P- domains during the catalytic cycle [21]. 
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Detailed information about the SERCA structure helped to build the models describing PMCA 
structure and function [22].  
SERCA1 is most abundant in the skeletal muscle, giving almost 50% of membranes proteins 
of muscle cells, and being accountable for around 40% of their metabolic rate. SERCA1 has 
two isoforms generated by the alternative splicing of its exon22. SERCA1b is present during 
neonatal development, while SERCA1a is expressed in adults [23, 24].  SERCA2 has four 
known isoforms among which SERCA2b has a housekeeping function and it is expressed in a 
lower amount but ubiquitously. SERCA2a, c and d are all expressed in the heart. SERCA2a 
isoform is most abundant in the cardiac muscle but also present in other muscle types and 
neuronal cells [25]. SERCA3 is the most recently identified and the least known member of 
the family. It differs from the other two SERCA pumps by having a five-fold lower affinity 
toward Ca2+. Its expression is widespread but it is found always together with the 
housekeeping form SERCA2b which makes possible to fine tune the ER Ca2+ uptake. The 
expression of SERCA3 is known to be altered in several cancer types [26]. It is abundantly 
expressed in normal colon, breast and bronchial epithelium however its expression is lost 
during the carcinogenesis of these tissues [27-29]. Treatment of colon, breast or lung cancer 
cell lines with histone deacetylase inhibitors was shown to induce SERCA3 expression 
together with differentiation. These data suggest that SERCA3 is an important regulator of 
differentiation and its loss contributes to malignant transformation. 
2.2.2. Plasma membrane Ca2+- transport ATPase (PMCA) 
There are four plasma membrane Ca2+ ATPases (PMCA1-4) coded by four different genes 
(ATP2B1-4) which all localize on different chromosomes. PMCAs become activated by the 
increase of the cytosolic Ca2+ concentration and their main role to pump excess Ca2+ out 
from the cytosol. They use one ATP to transport one Ca2+ [30]. Nevertheless, there is a great 
functional diversity among these pumps which is further increased by the generation of over 
20 splice variants through alternative splicing at two splice sites (Figure 2) [31]. Their general 
structure consists of 10 transmembrane helices and three intracellular domains.  
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Figure 2. Schematic model of plasma membrane Ca2+ ATPase [32]. The PMCA has ten 
transmembrane helices (on the top), a small intracellular loop including splice site ´A´ and an 
acidic lipid binding region (AL). In the large intracellular loop there is the ATP binding site 
(ATP) and the catalytic phosphorylation site (P).The calmodulin binding sequence (CBS) and 
the ´C´splice site are found in the C-terminal tail. Below the splice variants of PMCA4 at splice 
cite ´C´ and the splice variants of PMCA2 at splice cite ´A´ are shown. 
  
Splice site A and the acidic lipid binding region (AL) are found in the small intracellular loop, 
which according to the SERCA structure forms the A domain. The ATP binding region and the 
catalytic phosphorylation site are located in the large intracellular loop forming the N and P 
domains, respectively. The C-terminal tail contains the calmodulin binding site (CBS), which 
overlaps with splice site C. In the resting state the C-terminal tail strongly interacts with the 
catalytic domains and serves as an autoinhibitor [32]. Splicing at site C affects the interaction 
of the C-terminal tail both with Ca2+-calmodulin (Ca2+-CaM) and the core regions and 
determines the basal activity of the pump. In general PMCAs with an ´a´ insert have a higher 
basal activity and lower CaM affinity than the ´b´splice variant without the insert. Since the 
strength of the interaction also depends on the sequence composition of the catalytic region 
large differences can be found among the same splice variants of the different isoforms. For 
instance, PMCA4b has a lower basal activity and hence a stronger activation by Ca2+-CaM 
than PMCA2b [31]. Alternative splicing at the C-terminal region also affects the regulation of 
the pump by other means such as phosphorylation by protein kinases and interaction with 
other proteins. The splice site A variants differ in their intracellular targeting; for example 
the PMCA2 proteins with a ´w´ insert are targeted to the apical membrane in polarized 
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epithelial cells, while the ´x´variants have basolateral localization [33]. Amino acid sequence 
differences also influence the interaction with acidic phospholipids in the AL region close to 
splice site ´A´. Because of all these differences a toolkit of PMCA proteins is generated in 
which each member differs in its activation kinetics, interaction partners and regulation. 
The functional diversity is coupled with distinct developmental, tissue and cell type specific 
distribution (Table 1) [31, 34].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Human PMCA isoforms and splice variants (Based on [31, 34].) 
 
PMCA1x/b is considered as the housekeeping isoform and appears the earliest during mouse 
embryonal development. Homozygous deletion of the ATP2B1 gene in mice causes 
embryonic death [35]. However the other splice variants of PMCA1 protein are only 
expressed in specific cell types mostly in the brain and in striated muscle. PMCA4x/b is also 
ubiquitously expressed, while other PMCA4 variants are mostly found in the heart and in 
smooth muscle. Loss of both copies of the ATP2B4 gene causes complete male infertility in 
mice [35]. PMCA2 and PMCA3 are mostly expressed in excitable cells, and so they 
abundantly found in the brain and in skeletal muscles. Some of them are present in very 
specialized cell types, like PMCA2w/a in auditory and vestibular hair cells [36] while 
Isoform Alternative 
splice variants 
Major sites of expression Gene knockout phenotype 
(mouse) 
 
 
PMCA1 
x/a 
x/b 
x/c 
x/d 
x/e 
Brain 
Ubiquitous, lung, kidney 
Skeletal muscle, heart 
Skeletal muscle 
Brain 
Embryonic lethal 
(homozygotes); altered 
smooth muscle Ca
2+
 
regulation (heterozygotes) 
 
 
 
PMCA2 
w/a 
x/a 
z/a 
w/b 
 
x/b 
z/b 
Brain, cochlear outer hair cells 
Brain 
Brain 
Brain, lactating mammary epithelial 
cells 
Brain, spinal cord 
Brain 
Profoundly deaf, severe 
ataxia, reduced milk Ca
2+
, 
motor neuron loss 
(homozygotes) 
 
PMCA3 
x/a 
z/a 
x/b 
z/b 
Brain, spinal cord 
Brain, pancreatic beta cells 
Brain, Skeletal muscle 
Brain 
Not determined 
 
 
 
PMCA4 
x/a 
z/a 
x/b 
z/b 
x/d 
z/d 
x/e 
z/e 
Smooth muscle, bladder, heart  
Smooth muscle, heart 
Ubiquitous, heart, kidney 
Heart 
Heart 
Heart 
Brain, bladder 
Brain, bladder 
Male infertility due to 
sperm motility defect 
(homozygotes)  
14 
 
PMCA2w/b in the lactating mammary glands. The phenotype of ATP2B2-/- mice is ataxia, 
profound deafness [37] and reduced Ca2+ content in milk [38]. Furthermore, often multiple 
PMCA isoforms are present simultaneously in a cell having different expression level and 
subcellular localization. For example in cochlear hair cells in the inner ear PMCA2w/a is 
specifically targeted to the apical stereocilia while PMCA1x/b resides in the basolateral 
membrane [39].  
2.2.2.1. Regulators of PMCA activity 
The primary regulator of PMCA activity is the Ca2+- calmodulin complex. When the 
intracellular  Ca2+concentration rises, each CaM molecule binds 4 Ca2+ ions and Ca2+-CaM 
complexes are formed. The binding of Ca2+-CaM to the C-terminal region of the PMCA 
induces a conformational change in the protein and thus the connection between the 
inhibitory region and the catalytic domains is relieved and the pump becomes active [40]. 
The kinetics of the binding of Ca2+-CaM to the most common PMCA isoforms was heavily 
investigated. It was found that PMCA4b binds the Ca2+-CaM complex slowly and also 
dissociates it slowly, only after a couple of minutes. However, PMCA4a, which has another 
splice variant in its CaM binding sequence, binds Ca2+-CaM quickly but then dissociates it 
faster [41], resulting in an overall lower affinity (relatively high Kd) for the Ca
2+-CaM complex 
than the other splice form. The PMCA2 and PMCA3 pumps, which are common in excitable 
cells, both have fast activation and slow inactivation kinetics, resulting in tight Ca2+-CaM 
binding (low Kd) [42]. Pumps with a slow inactivation rate have a longer memory of the 
earlier Ca2+ spike, which means that if subsequent signals come quickly the pumps are still 
active and can act promptly. 
Acidic phospholipids are also important regulators of PMCA proteins. PIP2 
(phosphatidylinositol-4,5- bisphosphate) is an important signaling molecule and a known 
regulator of different pumps and channels. PIP2 can be hydrolyzed by the Ca
2+- dependent 
PLC into diacyglycerol (DAG) and IP3, of which the latter induces Ca
2+ release from the 
internal stores [43]. Previously, two acidic lipid binding regions were identified, one close to 
splice site ´A´ and another in the CBS region within the C-terminal tail. Recently, with 
homology modelling of PMCA4b a third PIP2 binding area was described, within the stalk 
region of the pump. This region formed by positively charged residues creates several 
binding pockets for the inositol ring of the PIP2 molecule. It was demonstrated that by 
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binding PIP2 molecules PMCA4b can influence the amount of available PIP2 for intracellular 
signaling. Furthermore, it can directly decrease PLC activation providing a second layer of 
protection by pumping out Ca2+ from the vicinity of the bound PIP2 molecules [44].  
The activity of PMCA proteins is also dependent on their abundance in the plasma 
membrane. It was shown that PMCA4b mostly resides in the intracellular compartments in 
sub-confluent cell cultures, while at confluency it translocates to the plasma membrane. A 
di-leucine sorting signal was identified in the C-terminal tail of the pump (1167LLL) that 
regulates its internalization to early endosomes after loss of cell-cell contact. Alternation of 
this motif to three alanines increased the plasma membrane localization of PMCA4b in sub-
confluent cells and changed the trafficking of PMCA4b after internalization [45]. 
Phosphorylation can also change the activity of PMCAs. Several phosphorylation sites for 
protein kinases A and C were described in the C-terminal tail of these pumps. The effect of 
phosphorylation is isoform dependent as it can both increase and decrease the activity of 
the pumps [46, 47]. 
There are cleavage sites for both calpain and caspase-3 proteases in the C-terminal tail of 
PMCA. Proteolytic cleavage of this region releases the autoinhibition of the pump [48]. 
During apoptosis caspase-3 activity removes the complete inhibitory region and the pump 
becomes fully active [49]. This might help to avoid excessive Ca2+ overload and consequently 
necrotic death of the cells [50]. 
2.2.2.2. Interactions with scaffold proteins 
Several protein partners of PMCAs have been identified. On the one hand these protein-
protein interactions can influence the activity of the pump, on the other hand they can 
target PMCAs into specific membrane microdomains or signaling platforms. One of the most 
important interaction sites is the PDZ-binding sequence at the C-terminus of each b-splice 
variant. PDZ proteins have scaffolding and anchoring roles creating platforms for protein-
protein interactions or linking proteins to the cytoskeleton. PMCA1b, 2b and 3b carry an 
identical PDZ-binding sequence (-ETSL). PMCA2b was shown to interact with the scaffold 
protein Na+/H+ exchanger regulatory factor 2 (NHERF2) [51]. It was demonstrated that in 
polarized MDCK cells “w” A-splice variant PMCA2w/b localizes to the apical membrane and 
this is stabilized by NHERF2-binding that anchors the pump to the actin cytoskeleton [52]. 
The PDZ-binding sequence of PMCA4b is different in one amino acid residue (-ETSV), and it 
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interacts with different PDZ proteins. Co-expression of membrane-associated guanylate 
kinase (MAGUK) scaffold family member PSD-95 (post synaptic density protein) and PMCA4b 
in COS-7 cells resulted in the redistribution of the pump into clusters which were fenced by 
the actin cytoskeleton and hindered the lateral mobility of the protein [53, 54].  
2.2.2.3. Interactions with signaling molecules 
PMCAs by interacting with other proteins are also able to regulate downstream signaling 
events. The protein partners come into contact with different regions of the pump. Through 
its PDZ-domain PMCA4b interacts with the neural nitric oxide synthase (nNOS) molecule.  
PMCA4b was shown to decrease nNOS activity and as a consequence also -adrenergic 
stimulation of cardiomyocytes in mice [55]. Interestingly, this effect is not related to the 
pump’s Ca2+ extruding capacity, in this respect PMCA has a structural role by tethering nNOS 
into a special membrane compartment of the cardiac cell [56]. 
Interactions with the N-terminal segment of the pump were also described. For example a 
regulatory protein 14-3-3ε can bind to this region and inhibit the activity of PMCA4 [57]. 
Several proteins were found to interact with the large intracellular loop as well. Tumor 
suppressor Ras effector protein, RASSF1 was found to directly interact with PMCA4b in a 
yeast two hybrid screen system. Co-expression of the two proteins inhibited the activation of 
the ERK pathway in the cells after activation with epidermal growth factor (EGF) [58].  
Also association of PMCA and endothelial nitric oxide synthase (eNOS) was demonstrated 
through the catalytic loop which led to the inhibition of eNOS activity and NO production in 
endothelial cells [59].  
There is ample evidence in the literature that PMCA can regulate the activity of the 
calcineurin (CaN) / NFAT (nuclear factor of activated T-cell) pathway. Calcineurin is a 
Ca2+/CaM dependent serine/threonine protein phosphatase which can activate the NFAT 
transcription factor family [60]. It was shown that both PMCA4 and PMCA2 directly interact 
with calcineurin through their catalytic core region which results in a reduced NFAT 
activation. It was hypothesized that this effect is achieved by keeping the bound calcineurin 
in a low Ca2+ environment [61, 62]. Furthermore, in osteoclasts an autoregulatory loop was 
described between PMCA1 and 4 and NFATc1, where NFATc1 directly binds to the promoter 
region of these PMCAs and induces their expression while PMCA activity reduces cytosolic 
Ca2+ oscillations, hence NFAT activation [63]. Additionally, in endothelial cells PMCA4b was 
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described to decrease NFAT activation after vascular endothelial growth factor (VEGF) 
induction. PMCA4 also reduced endothelial tube formation of mouse lung endothelial cells 
both in vitro and in vivo [64].  
An interaction of PMCA and a scaffold protein POST (Partner of STIM) in T-cells was also 
described. POST was discovered as a binding partner of the ER Ca2+ sensor molecule STIM1. 
It is also able to bind to other proteins including SERCAs, PMCAs and Na+/K+-ATPases thus 
creating multimolecular complexes. Upon interaction with the PMCA POST lowers the 
activity of the pump and in this way it helps to maintain the elevated intracellular Ca2+ 
concentration upon T-cell stimulation [65]. 
All these findings revealed that PMCA proteins are important members of the intracellular 
signaling network and besides removing excess Ca2+ from the cytosol they are able to 
influence specific signaling pathways. 
 
2.3 Alternations of Ca2+ transport in cancer 
During the malignant transformation cells acquire the features of cancer cells. These 
features are called as the hallmarks of cancer [66], which are the sustained proliferative 
signaling, avoidance of cell death, resistance against anti-proliferative signaling, replicative 
immortality, stimulation of angiogenesis, invasive capacity and ability to form metastasis, 
altered energy metabolism and avoidance of the immune response.  Ca2+ plays an important 
role in the regulation of many of these processes in healthy cells, and alterations of several 
Ca2+ handling proteins were described in cancer cells. These alterations can modify not only 
the spatial and temporal features of the intracellular Ca2+ changes but also the steady state 
Ca2+ level of the subcellular compartments resulting in both cases in an altered activation of 
downstream signaling pathways [67]. 
2.3.1. The role of Ca2+ in tumor cell survival   
Ca2+ plays an important role in the regulation of cell cycle in healthy cells. Early in the G1 
phase, elevation of cytosolic Ca2+ concentration is required for the initiation of the cell cycle 
through the activation of transcription factors c-fos, c-jun, myc and NFAT. These 
transcription factors regulate the expression of cell cycler regulator cyclin dependent kinases 
(CDK2 and 4) and cyclins (D and E). During the G1/S transition phase Ca2+ is required for the 
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phosphorylation step of the retinoblastoma checkpoint protein that causes its inactivation. 
Furthermore, during the G2/M transition Ca2+ oscillations regulate centrosome separation 
through CaMKII  (Ca2+/calmodulin-dependent protein kinase II) activity [68].  
In cancer cells the activity of several Ca2+-dependent transcription factors is sustained 
initiating constant growth. The reason for the sustained growth activation can be the 
increased Ca2+ inflow to the cell [69]. For example in prostate cancer cells transient receptor 
potential cation channels TRPC6 and TRPV6 have been shown to induce the activation of the 
NFAT signaling pathway and TRPV6 was identified as a prognosticator for tumor progression 
[70]. Members of SOCE were found to enhance cell growth in several types of cancer such as 
breast, prostate, colorectal and cervical cancer [71]. For example, Orai3 channel was 
reported to be overexpressed in breast, lung and prostate cancer. In MCF-7 breast cancer 
cells, Orai3 was found to increase cell cycle progression through the induction of proto-
oncogene c-myc [72]. In prostate cancer cells, Orai3 and Orai1 form heterotetramers that 
can be activated by arachidonic acid (AA) independently from store depletion. This, on the 
one hand, induces the calcineurin-NFAT pathway, which ultimately activates cyclin D1 and 
proliferation. On the other hand, it contributes to the avoidance of apoptosis by decreasing 
the ratio of the homomeric Orai1 channels, which are necessary for apoptosis induction 
through SOCE [73]. 
It has been known for a long time that Ca2+ plays an important role in the regulation of cell 
death. There are several different forms of cell death including apoptosis, autophagy and 
necrosis. Ca2+ overload in the mitochondria and Ca2+ depletion of the ER both can trigger 
apoptosis, while excessive cytoplasmic Ca2+ overload can induce necrosis [74]. During 
autophagy, a process with particular importance in both cancer cell death and resistance, 
Ca2+ was shown to regulate autophagosome formation and it can activate the death-
associated protein kinase (DAPK), one of the major regulatory protein of autophagy [75]. 
There is a cross-talk among these processes and they can be present in a given tissue, 
simultaneously.  
Cancer cells are able to avoid cell death through altered regulation of Ca2+ handling 
molecules. For example, the decreased expression and/or activation of plasma membrane 
Ca2+ channels can reduce the chance of a Ca2+ overload after apoptotic stimuli. In androgen 
independent prostate cancer cells, the expression of Orai1 and STIM1 proteins were found 
to be decreased resulting in decreased SOCE [76]. This was coupled with adaptation to a 
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reduced Ca2+ level in the ER because of the reduced expression of the ER Ca2+ binding 
protein calreticulin and the SERCA2b pump [77].  
However, increased expression of Ca2+ channels can also lead to apoptosis resistance either 
by inhibiting pro-apoptotic pathways or by directly refilling ER stores with Ca2+ and in this 
way avoiding ER depletion caused ER stress. For example, in breast cancer cells, Orai3 
initiated c-myc activation induces not only proliferation but it also decreases the expression 
of the pro-apoptotic Bax protein [78]. While in certain astrocytoma cells TRPV1 channels are 
highly expressed both in the plasma membrane (PM) and in the ER membrane and activation 
of these channels induces apoptosis by initiating ER stress [79].  
Ca2+ released from the ER through IP3R channels can be directly taken up by the 
mitochondria in their contact sites which can initiate permeability transition pore (PTP) 
opening and cytochrome-c release. Consequently, resistance can come from the decreased 
expression or activation of IP3Rs.This was observed in cisplatin resistance bladder cancer 
cells where decreased expression of IP3R1 prevented apoptosis [80]. Furthermore, it was 
demonstrated that anti-apoptotic protein Bcl-2 can directly interact with IP3Rs and inhibit 
their activities [81]. 
2.3.2 The role of Ca2+ in tumor cell migration and metastasis 
Ca2+ is a key regulator of cell migration in healthy cells. In migrating cells, an increasing Ca2+ 
gradient is generated from the front, where protrusions are developed, towards the rear end 
of the cell, where the trailing edge is retracted. This makes possible to differentially regulate 
Ca2+-dependent modulators of the migratory process along the polarized cell [82]. One such 
modulator is the Ca2+-dependent myosin light chain kinase (MLCK), which by 
phosphorylating the regulatory light chain of myosin II initiates contraction. Focal adhesions 
(FA) connect the cytoskeleton of the cell with the extra cellular matrix (ECM). For cell 
motility, FAs need to be assembled in the front and disassembled in the rear. This is primarily 
controlled by focal adhesion kinase (FAK) which is a non-receptor tyrosine kinase.  FAK 
activity is regulated directly by local Ca2+ changes in the focal adhesion site [83] and also 
through the calcium/calmodulin-dependent kinase II [84]. Furthermore, the Ca2+-dependent 
protease calpain 2 also regulates FAK activity by proteolysis [85]. In the leading edge of 
fibroblasts, stretch-activated TRPM7 channels together with IP3R channels in the ER 
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generate local Ca2+ flickers, which are necessary for directed migration toward 
chemoattractants [86].  
Meyer et al. investigated in detail the spatial distribution and polarized function of Ca2+ 
regulating molecules in the leader cells of collectively migrating human umbilical vein 
endothelial cells (HUVECs) [87]. They found that receptor tyrosine kinase signaling was 
increased in the front of the cells and this led to a similarly polarized activation of PLC and 
generation of IP3 and DAG. This activity generated local Ca
2+ pulses in the front that induced 
MLCK activity. They showed that the global - toward the rear increasing - Ca2+ gradient was 
also present in these cells. Furthermore, the low global Ca2+ concentration in the front was 
the result of the enhanced Ca2+ extrusion capacity of the PMCA proteins, which localized 
mostly in the front of the cells. It was presented that the localization of the ER Ca2+ sensor 
molecule STIM1 also shifted towards the front, which was coupled with a decreasing Ca2+ 
level in the ER lumen. 
Metastasis is the major cause of cancer related death and cell migration is a prerequisite for 
metastasis. While in cancer cells the same set of Ca2+ signaling molecules are present as in 
normal cells, their activity and expression are often remodeled [82]. Increased Ca2+ intake 
through plasma membrane Ca2+ channels was shown to enhance cell migration in several 
cancer types [69]. For example, in metastatic prostate cancer, increased expression of TRPV2 
channel was found when compared to the primary tumor. Elevated expression of TRPV2 
increased the motility of the cells and the production of invasion associated enzymes, MMP9 
and cathepsin B [88]. SOCE was shown to be necessary for enhanced migration and 
metastasis of MDA-MB-23 breast cancer cells. Downregulation of Orai1 and STIM1 
expression or activity decreased cell migration and metastatic potential, in vivo [89]. In the 
lung cancer cell line A549 EGF treatment induced the expression of TRPM7 channel. 
Inhibition of TRPM7 activity and/or expression reduced the migratory potential of the cells 
[90]. ER Ca2+ receptor channel IP3R3 expression was found to be elevated in glioblastoma 
cells and inhibition of IP3R3 by caffeine decreased cell motility both in vitro and in vivo [91]. 
2.3.3 Remodeling of PMCAs in cancer 
Changes in the expression and the activity of PMCA proteins were described in several types 
of cancer, however, their role in carcinogenesis is isoform dependent. PMCA4b expression 
was found to be downregulated unanimously in cancer cells from various tumor types. 
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Strong decrease of PMCA4 expression was found in lymph node metastasis of colorectal 
cancer when compared to normal tissue and adenomas [92]. Furthermore, differentiation of 
colon cancer cell lines with short chain fatty acids, trichostatin A or by spontaneous 
differentiation strongly increased PMCA4b expression of the cells [93]. Similarly, PMCA4b is 
abundantly expressed in normal breast epithelium but it is present in a very low amount in 
breast cancer cells. Differentiation of breast cancer cell line MCF-7 with histone deacetylase 
inhibitors also enhanced the expression of this pump [94]. These results suggest that 
PMCA4b expression strongly correlates with the degree of differentiation of cells.  
In the case of PMCA1, the results are more controversial. In oral cancer cell lines its 
expression was found strongly downregulated by increased methylation in its promoter 
region, and its amount was also decreased in primary oral squamous cell carcinomas and in 
premalignant lesions [95]. PMCA1 protein level was also reduced in SV40-transformed 
fibroblasts compared to control cells [96] but a moderate increase in its mRNA level was 
detected in breast cancer cell lines [97]. It was demonstrated that PMCA1 was abundantly 
present in colon cancer cells and its expression only moderately increased after treatment 
with differentiating agents [93, 98]. 
Alterations in PMCA2 protein expression was described in breast cancer cells. In healthy 
breast tissue, PMCA2 is only expressed during lactation. However increased expression of 
PMCA2 mRNA was detected in several breast cancer cell lines [99]. It was suggested that the 
higher abundance of PMCA2 decreased the basal cytosolic Ca2+ concentration in these cells 
that resulted in a decreased susceptibility of the cells for apoptosis. PMCA2 was found to 
interact with calcineurin-A in the human breast cancer cell line MCF-7 and this interaction 
decreased the activity of transcription factor NFAT in the cells [62]. Inhibition of the 
PMCA2/calcineurin interaction induced the expression of the proapoptotic protein Fas 
Ligand on the cell surface and increased apoptosis of the cells [100].  
All these changes of Ca2+ handling molecules might not be the driving causes of cancer 
formation but rather consequences, nevertheless, they help to sustain cancer hallmarks. 
Better understanding of their function and modulation helps to identify new biomarkers or 
drug target molecules. 
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2.3.4. The effect of HDAC inhibitor treatment on PMCAs in cancer cells 
In eukaryotes, genomic DNA together with histone proteins is organized into the chromatin. 
The DNA strand is coiled around the globular nucleosomes formed by histone H3, H4, H2A 
and H2B proteins that are connected by linker histone H1. During gene expression this 
structure needs to loosen in order to RNA polymerase II binding [101]. Postsynthetic 
modification of the DNA and/or posttranslational modification of histone proteins can alter 
gene expression a phenomenon named epigenetic regulation. These alternations of the 
chromatin are reversible, changing during development and are affected by environmental 
factors. In the DNA, cytosines in CpG sequences can be methylated and when CpG islands in 
promoter regions are methylated that can lead to gene silencing. Remodeling of DNA 
methylation is often described in cancer cells [102].  
Histone proteins can go through various posttranslational modifications, like acetylation, 
methylation, phosphorylation or ubiquitylation. Histone acetyl transferases (HATs) are able 
to transfer an acetyl group to lysine residues in histone proteins. These acetylated lysines are 
specifically recognized by bromodomain containing proteins, such as helicases, 
methyltransferases, transcription coactivators and HATs themselves. Through the action of 
these proteins, histone acetylation influences chromatin remodeling and subsequently gene 
transcription, DNA replication and repair as well [103]. Increased acetylation of a chromatin 
region enhances DNA transcription there. In contrast histone deacetylases (HDACs) remove 
the acetyl groups from the lysine amino acids of histones. 18 different HDAC proteins were 
already described. Class I HDACs (HDAC1, HDAC2, HDAC3 and HDAC8) are found only in the 
nucleus, while class II HDACs shuttle between the nucleus and the cytoplasm (HDAC4, 
HDAC5, HDAC7, HDAC9, HDAC6 and HDAC10) and they all use Zn2+ as cofactor. Class III 
HDACs are the SIRT proteins that require NAD+ to their function. Since NAD+ production is 
dependent on the cellular nutrient levels, the activity of these HDACs is influenced by the 
metabolic state of the cells [104]. Beside histones they regulate acetylation of non-histone 
proteins as well. For example HDAC6 deacetylates -tubulin through which it regulates cell 
migration [105]. 
Since it was found that the expression and/or activities of HDACs are often increased in 
cancer cells, the antitumor effect of HDAC inhibitors was investigated [106]. Several different 
types of HDAC inhibitors were developed and it was demonstrated that they can affect 
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differentiation, apoptosis, motility, metastatic capacity and immunogenicity of cancer cells 
[107]. Hydroxamates – like trichostatin A (TSA) and suberoylanilide hyroxamic acid (SAHA or 
vorinostat) - interfere with HDAC activity by chelating the catalytic Zn2+. TSA was shown to 
induce differentiation or apoptosis in colon, gastric and prostate cancer cells [108, 109] and 
to enhance the effect of other antitumor drugs [110]. SAHA was approved as drug against 
cutaneous T cell lymphoma. Short chain fatty acids as butyrate or valproic acid (VPA) also 
has been shown to decrease tumor cell proliferation and increase cell death [111, 112]. VPA 
was already a known medication for epilepsy and seizures and its inhibitor effect on HDACs 
was only subsequently discovered. All the above mentioned HDAC inhibitors target multiple 
HDACs, lately several isoform selective HDAC inhibitors were developed and their clinical 
effect is currently investigated [107]. 
The influence of HDAC inhibition on PMCA expression has been examined in gastric, colon 
and breast cancer cell lines. It was demonstrated that after treatment with TSA or short 
chain fatty acids expression of PMCA4b was strongly increased in gastric and colon cancer 
cells while the abundance of PMCA1 isoform was only moderately elevated [93]. 
Spontaneous differentiation in post-confluent Caco-2 colon cancer cell cultures also induced 
PMCA4b expression. Similar results were obtained in breast cancer MCF-7 cells. PMCA4b 
was present in very low amount in control cells however treatment with valproate or SAHA 
caused a strong increase in PMCA4b expression. There was a higher amount of PMCA1b 
detected in the untreated cells, and its expression was only slightly elevated by the 
treatment [94].  
The effect of HDAC inhibitor treatment on melanoma cells was also investigated. On one 
hand it was found that HDAC inhibitors can induce cell death in melanoma cells by increasing 
the expression of pro-apoptotic proteins (BIM, BAX) and decreasing the anti-apoptotic ones 
(Bcl-2). On the other hand this effect was strongly cell line and agent dependent [113, 114]. 
In BRAF mutant melanoma cells combination treatment with BRAF inhibitor PLX4720 and 
SAHA increased the number of the apoptotic cells compared to single agent treatment. 
SAHA also sensitized resistant BRAF mutant cells to PLX4720 treatment induced apoptosis 
[115]. It was also found that HDAC inhibitor treatment affected the immunogenicity of 
melanoma cells. Pan-HDAC inhibitor (LHB589) increased the expression of MHC and co-
stimulatory molecules [116] while treatment with various class I HDAC inhibitors induced 
PDL-1 ligand expression on melanoma cells [117]. HDAC inhibitors were tested also in clinical 
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trials in metastatic melanoma patients however as single agents induced high level of 
toxicity. Since they were shown to increase immunogenicity and increase apoptosis in BRAF 
inhibitor resistant cells their applicability in combination therapies is currently investigated 
[118].  
 
2.4. Metastatic melanoma 
Incidence of melanoma is constantly rising worldwide but the white skin population in 
North-America, Australia and Europe is particularly susceptible for this disease [119]. In the 
USA, melanoma was one of the three most prevalent cancers among men in 2016 [120]. 
When melanoma is recognized in a localized stage the 5-year survival rate is 98%, however, 
among patients with regional metastasis it becomes 63% while with distant metastasis it is 
only 15% [119]. Surgical removal is the primary therapy for stage 0-II and resectable stage III 
melanomas. For unresectable stage III and IV cases a variety of targeted therapy, 
immunotherapy and chemotherapy are administered. Several new therapeutic options 
emerged in the last decade but the low percentage of long-term survivors shows the need 
for further research in this area. 
2.4.1. Melanoma development 
In the healthy skin, melanocytes are localized in the junction of the two layers of the skin, 
the epidermis and the dermis. The epidermis constitutes the barrier toward the outer 
environment through stratified keratinocytes, which are constantly renewed. The dermis 
provides nutrients and mechanical support. The basement membrane is localized between 
these two layers. The role of melanocytes is to produce melanin and transfer it to 
keratinocytes to provide protective cap over the nucleus against UV radiation. Melanocytes 
during development migrate to the skin from the neural crest where they develop several 
dendrites through which they are in connection with about 36 keratinocytes each. The 
proliferation capacity of melanocytes is tightly controlled by the surrounding keratinocytes 
[121]. 
Congenital nevi are present at birth and more nevi are commonly acquired during childhood. 
Dysplastic nevus shows histological abnormalities and regarded as a precursor towards 
cutaneous melanoma. The first malignant stage is the radial growth phase of melanoma 
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where cells rapidly proliferate and show local invasiveness. The second is the vertical growth 
phase of melanoma where cells spread already toward the subcutaneous tissue and the 
chance for metastasis is elevated. The final stage is when metastases are developed [122]. 
Melanoma cells in contrast to melanocytes do not develop dendrites and loss their contacts 
with keratinocytes, proliferate rapidly and express melanoma-associated antigens (MAA). 
This high immunogenicity of melanoma cells led to the discovery of several, not only 
melanoma specific, tumor associated antigens such as MAGE, and that makes melanomas a 
promising target of immunotherapy [123].  
2.4.2. Mutational landscape and targeted therapies 
Several oncogenic mutations were identified in melanoma and most of these can lead to the 
constant activation of mitogen activated protein kinase (MAPK) pathway. This pathway can 
be stimulated by external stimuli of epidermal growth factor (EGF), insulin-like growth factor 
(IGF) or transforming growth factor (TGF) through the receptor tyrosine kinase receptors in 
the plasma membrane, all of which activate the downstream small GTPase RAS proteins 
(HRAS, KRAS, NRAS). Ras proteins act on the downstream serine-threonine RAF kinases 
(ARAF, BRAF, CRAF), which turn on the MEK kinases that in turn activate ERK1 and ERK2. ERK 
proteins can traffic to the nucleus where they directly activate transcription factors such as 
ELK-1 inducing growth and survival [119]. Mutations in the NRAS gene were identified in 15% 
of melanomas [124], while in about 50% of the cases BRAF mutation was found. Among the 
many described BRAF mutations the V600E is particularly prevalent, where a glutamic acid is 
changed to a valine [125]. This mutation is found in more than 75% of the cases.  
Mutations with lower frequency were identified in other pathways as well. Inactivating 
mutation of the tumor suppressor protein PTEN is often present that enhances PIP3 
production and in this way the activation of the PI3K/Akt/mTOR pathway. Furthermore, 
activating mutations in the PI3K/Akt/mTOR pathway were also described. 
Since the constituent activation of the MAPK pathway is so frequently the driving force of 
melanoma cell survival and spread, specific inhibitors were developed against the BRAF and 
MEK kinases. Before these agents only the chemotherapeutic drug dacarbazine was available 
for patients with metastatic melanoma resulting in median overall survival around 5 months. 
Introduction of mutant BRAF (V600E) specific inhibitor vemurafenib and later dabrafenib 
initiated quick and high response rate (60%) and raised median overall survival to around 13 
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months. However, there were patients with intrinsic resistance and in most of the cases 
acquired resistance emerged within 6-8 months [126]. A number of molecular mechanisms 
have been described for the intrinsic resistance such as PTEN loss [127], cyclin D1 
amplification and stromal cells produced hepatocyte growth factor (HGF) stimulation 
through its receptor CMET. Acquired resistance mechanisms are induced by the BRAF 
inhibitor treatment. They can be either ERK-dependent like upregulation of the RTK 
receptors which results in the reactivation of ERK, or ERK-independent like the induction of 
the PI3K/Akt/mTOR pathway [126]. 
The other successfully targeted molecules in the MAPK pathways are MEK1 and MEK2. 
Several highly specific inhibitors were developed like trametinib and comibetinib, and since 
2014 the combination therapy of BRAF inhibitor dabrafenib and MEK inhibitor trametinib is 
approved for unresectable and metastatic BRAF mutant melanomas [128]. MEK inhibitors 
were also tested in clinical trials with NRAS mutant melanoma patients, however, their 
efficacy were unfortunately very low; combination of MEK inhibitors with PI3K-AKT or 
CDK4/6 inhibitors might increase the therapeutic benefit [124].   
Mutations of receptor tyrosine kinase C-KIT were also identified with lower frequency (2-5%) 
in cutaneous melanomas and trials with C-KIT inhibitor imatinib and sunitib were conducted 
and gave promising results [129].  
2.4.3. Immunotherapy to treat melanomas 
Most efficiently and least invasively the patient´s own immune system could eradicate 
cancer cells. However, tumor cells are able to evade or suppress immune response even if 
they are so immunogenic as most melanoma cells. Immunotherapies like treatment with 
cytokines (IL-2, IFN-) or adoptive cell therapy with ex vivo grown antitumor lymphocytes 
were already used in metastatic melanomas [123], however, the breakthrough was recently 
achieved with the use of immune checkpoint inhibitors. This method is based on the 
regulation of T-cell activation. CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) is a 
transmembrane receptor and its expression is increased after the activation of T-cells. It can 
interact with the costimulatory molecules B7 (CD80, CD86) expressed on the surface of the 
antigen presenting cells (APC) which counteracts with T-cell activation and induces anergy of 
the cell. Inhibition of this interaction by CTLA-4 specific antibody frees B7 molecules so they 
can interact with costimulatory receptor CD28 and enhance T-cell activation [130].  
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PD1 (programmed cell death receptor 1) receptors also conduct negative regulatory signals 
and are present not only in activated T-cells but also on B-cells and natural killer cells. 
Natural APCs and also cancer cells can express its ligands PD-L1 and PD-L2 and through this 
interaction decrease T-cell activity [119].  
CTLA-4 inhibitor ipilimumab was approved first in 2011, next PD-1 blockers pembrolizumab 
and nivolumab were introduced which generated higher response rate (~ 40%) and less 
toxicity. Currently, combination therapy with ipilimumab and nivolumab raised further the 
response rate over 50% however, serious adverse effects (AEs) were also more frequent (~ 
50%). Based on these results PD1 inhibitor nivolumab was approved as first-line therapy for 
PD-L1 positive tumors. Combination therapy with ipilimumab is proposed for patients with 
PD-L1 negative tumors because only for this subgroup of patients it was shown to be 
superior when compared to monotherapy [130].  
Of note, AEs rarely can be severe or lethal even with PD-1 inhibitors, and there are many 
patient who are intrinsic resistant to immunotherapy or acquire quickly resistance during the 
treatment. Further predictive biomarkers for sensitivity to immunotherapy still need to be 
identified.  
In the case of BRAFV600 melanomas both targeted therapy and immunotherapy is an 
option. Phase III clinical trials are ongoing to determine in which sequence it is better to 
employ them [130, 131].   
2.4.4. Ca2+ signaling in melanoma 
As it was discussed earlier the expression and activity of Ca2+ regulatory proteins are often 
altered in tumor cells. In melanomas, changes in the expression of several Ca2+ channels and 
consequently alternations in Ca2+ signaling were described [132].  
TRPM1 (transient receptor potential melastatin 1) channels are very important regulators of 
normal melanogenesis and are abundantly expressed in normal melanocytes and in benign 
nevi. However, their expression is strongly decreased in primary melanomas and they are 
absent in metastases. It was found that TRPM1 level negatively correlates with tumor 
aggressiveness and TRPM1 mRNA level might be used as a predictive marker for future 
metastases. Its expression was shown to be under the control of transcription factor MITF, 
which is a known regulator of melanocyte differentiation and it is often downregulated in 
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melanoma cells. TRPM8, TRPM2 and TRPM7 were all found to be upregulated in melanoma 
cells where they contributed to increased proliferation and metastatic capacity [133]. 
SOCE is the most common Ca2+ entry mechanism is non-excitable cells. Elevated expression 
of store operated Ca2+ channel Orai1 and stromal interacting molecule 2 (STIM2) was 
described in both melanoma cell lines and melanoma tissues and silencing of these proteins 
decreased the metastatic and migratory potential of these cells but increased their 
proliferation [134]. In another study, Orai1 and STIM1 were found to be upregulated in 
melanoma cells which was associated with the enhanced activity of the CaMKII/Raf-1/ERK 
signaling pathway. Furthermore, inhibition of SOCE decreased both melanoma cell 
proliferation and migration [135]. In both studies, the effect of SOCE on melanoma cells was 
independent of their BRAF mutational status.  
A specific mechanism was described by Sun et al. through which SOCE influence cell 
migration and metastasis in melanoma cells. They found that STIM1 and Orai1 initiate 
Ca2+oscillations which regulate invadopodium assembly through phosphotyrosine Src 
activation and ECM degradation by increasing MMP production [136].  
Voltage-gated T-type Ca2+ channels were also found to be upregulated in melanoma cells 
that was shown to enhance proliferation [137]. Clinically used T-type channel blockers 
caused decreased proliferation and autophagy and induced apoptosis in melanoma cell lines 
[138].  
Since Ca2+has a diverse effect on cell migration, it is an important regulator of melanoma cell 
motility, as well. A guanine nucleotide exchange factor Epac (exchange protein directly 
activated by cyclic AMP) increases melanoma cell migration by inducing Ca2+release from the 
ER and ultimately increasing intracellular Ca2+ level. This effects cell motility by increasing 
actin assembly [139]. It was also presented that cGMP-specific phosphodiesterase PDE5A is 
downregulated in BRAF mutant melanoma cells that results in cytosolic Ca2+elevation. This 
led to increased contractility of the cells through enhanced phosphorylation of myosin light 
chain 2 and to enhanced metastatic potential in lung colonization assay [140].  
Elevated expression of Ca2+/calcineurin activated transcription factor NFAT2 and NFAT4 was 
found in BRAF mutant melanoma cell lines which directly increased cyclooxygenase-2 (COX-
2) transcription. COX-2 is a known positive regulator of cancer cell migration and invasion 
and often associated with poor prognosis [141].  
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Ryanodine receptor RyR2 and ligand gated Ca2+ channel P2X7 were also shown to be 
upregulated in BRAF mutant melanoma cells. Ryr did not function as a Ca2+ channel but it 
modulated P2X7 function while P2X7 had an antiapoptotic effect after simultaneous 
stimulation with apoptosis inducer  2-methoxyestradiol (2ME) and its agonist ATP. However, 
after downregulation of P2X7 expression with siRNA the cells became sensitized to 2ME 
treatment [142]. 
It was also suggested that inhibition of SERCA pumps can contribute to the induction of 
apoptosis in BRAF inhibitor resistant melanoma cells. They found that in BRAF mutant 
melanoma cells BRAF inhibitor treatment causes an increase in the basal cytosolic Ca2+ level 
which induces ER stress and apoptosis. This effect could be further increased by the addition 
of SERCA inhibitor thapsigargin even in vemurafenib resistant cells [143].  
Nevertheless, the role of plasma membrane Ca2+ pumps in melanoma progression has not 
been investigated until now. 
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3. Aims 
 
PMCA proteins are key regulators of intracellular Ca2+ homeostasis in all cell types. They 
differ in their kinetic and regulatory features that define their ability to respond to a variety 
of incoming Ca2+ signals. By shaping intracellular Ca2+ transients and through interactions 
with other molecules, PMCA proteins play a role in the regulation of crucial cellular 
processes such as differentiation, migration or cell death. 
  
In this work we wanted to examine how different PMCA isoforms shape the cytosolic Ca2+ 
signal and investigate if PMCA proteins play a role in Ca2+ signaling of metastatic melanoma 
cells. In order to study this: 
1. We analyzed the differential effects of PMCA isoforms PMCA4b, PMCA4a and 
PMCA2b on the pattern of the SOCE induced Ca2+ signal. Therefore, we expressed 
mCherry-tagged PMCA variants together with the genetically encoded Ca2+ indicator 
GCaMP2 in Hela cells.   
2. We studied the influence of PMCA proteins on Ca2+ signaling in both BRAF mutant 
and BRAF wild type melanoma cells. We determined the expression pattern of the 
PMCA proteins and analyzed the effect of mutant BRAF inhibitor treatment on the 
PMCA expression, localization and the intracellular Ca2+ signal. 
3. Since metastatic melanoma cells are highly motile we aimed to analyze the effect of 
mutant BRAF inhibition on the migratory capacity of melanoma cells. 
4. We investigated how PMCA affected the motility of melanoma cells. Therefore, we 
generated BRAF mutant cell lines overexpressing PMCA4b and tested their migratory 
characteristics in vitro, and their metastatic capacity in vivo. 
5. Since HDAC inhibitor treatment has been shown to induce PMCA4b expression in 
breast and colon cancer cells, we treated the melanoma cells with HDAC inhibitors 
alone or in combination with the mutant BRAF inhibitor. We examined the 
expression, localization and activity of the PMCA, and determined the migratory 
activity of the cells in response to the HDAC inhibitor treatments. 
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4. Materials and methods 
4.1 Cell culture 
In our experiments we used the HeLa cervix adenocarcinoma cell line and four melanoma 
lines: the BRAF/NRAS wild type MEWO, the NRAS mutant MJZJ and the two BRAF mutant 
A375 and A2058 cells. MEWO, A375 and A2058 cell lines were obtained from the American 
Type Culture Collection, MJZJ was established at the Institute of Cancer Research at the 
Medical University of Vienna [144]. Cells were grown in Dulbecco’s modified Eagel’s Medium 
(DMEM) supplemented with 10% FBS, 100 mg/ml streptomycin, 100 U/ml penicillin at 37oC 
and 5% CO2 in a humidified atmosphere. 
4.2 Transfection of HeLa cells and generation of stable cell lines 
For the Ca2+ signal measurements, HeLa cells were transiently co-transfected with one of the 
mCherry-PMCA4b, mCherry-PMCA4b-LA, mCherry-PMCA4a or mCherry-PMCA2b constructs 
and the pN1- GCaMP2 plasmid. The mCherry-PMCA constructs were generated as described 
in [44, 45], the pN1-GCaMP2 plasmid was a gift from Junichi Nakai, RIKEN Brain Science 
Institute, Saitama, Japan [145]. Cells were seeded in an Imaging Chamber Lab-Tek II (Nalge 
Nunc International) at a 4-6x104 cells/well concentration 24 hours before transfection. 
Transient transfections were performed with transfection reagent FuGENE HD (Roche 
Applied Science) according to the manufacturer’s protocol. Measurements were carried out 
48 hours after transfection. 
The sh-HeLa cell line was created by stable transfection with PMCA4 shRNA plasmid (sc-
42602-SH) and shRNA plasmid-A (sc-108060) was used as control. Cells were seeded in a six-
well plate and before transfections medium was changed to the shRNA Plasmid Transfection 
Medium (sc-108062). Transfection was carried out with shRNA Plasmid Transfection Reagent 
according to the manufacture’s protocol. To select successfully transfected cells Puromycin 
dihydrochloride (1μg/ml) (sc-108071) was added to the medium 48 hours after transfection. 
In every 2-3 days, medium was changed to fresh medium with Puromycin for two weeks. 
Then cell clones were generated using cloning rings and PMCA4b protein level was analyzed 
by Western Blotting. Sh-HeLa cell lines with lowest PMCA4b expression were established. 
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4.3 Transfection of melanoma cells and generation of stable cell lines  
For the melanoma studies A375-GFP, A375-GFP-PMCA4b I, A375-GFP-PMCA4b II, MEWO-
GFP and MEWO-GFP-PMCA4b cell lines were generated by stable transfection with SB-CAG-
GFP-PMCA4b-CAG-Puromycin or SB-CAG-GFP-CAG-Puromycin vectors that include a Sleeping 
Beauty transposon system. These vectors were created by the modification of SB-CAG-GFP-
ABCG2-CAG-Puromycin vector (a generous gift from T. Orban [146]) from which the GFP-
ABCG2 insert was cut out with AgeI and BclI enzymes. The GFP-PMCA4b sequence was 
excised from the pEGFP-PMCA4b plasmid [33] by first opening the vector with ClaI enzyme 
digestion and then with a partial digestion with AgeI and BamHI. Afterwards GFP-PMCA4b 
was ligated into the open SB-CAG-CAG-Puromycin vector. Stable transfection with the SB-
CAG-GFP-PMCA4b-CAG-Puromycin was performed by first seeding 2-3.5x105 MEWO and 
A375 cells/well on 6-well plates. 24 hours later SB-CAG-GFP-PMCA4b-CAG-Puromycin vector 
and SB100x transposase plasmid were added to the cells in 1:10 ratio together with Fugene 
HD transfection reagent (Roche Applied Science). 48 hours later selection of transfected cells 
started with 1µg/ml puromycin dihydrocloride. 
4.4 Treatments of melanoma cells 
Mutant BRAF (V600E) inhibitors vemurafenib (PLX4032) and GDC0879, and the MEK kinase 
inhibitor selumetinib were obtained from Selleck Chemicals (Munich, Germany). All these 
inhibitors were dissolved in DMSO and kept at -80oC. HDAC inhibitors valproic acid sodium 
salt and suberoylanilide hyroxamic acid (SAHA) were purchased from Sigma-Aldrich. 200 mM 
stock solution of valproate was prepared in distilled water while SAHA was dissolved in 
DMSO at 100 mM concentration. Both were stored at -20 oC. Cells were seeded 24 hours 
before treatment either on 6-well plates (1-2x105 cells/well) or into imaging chambers (1-
2x104 cells/well). The appropriate drug was applied in fresh medium the next day and cells 
were cultured for the appropriate period of time. SAHA was replaced daily in fresh medium. 
The final DMSO concentration was lower than 0.01% in all experiments. 
4.5 Ca2+ signal measurements 
In order to detect the changes in the intracellular Ca2+ concentration, HeLa cells were 
transfected with the genetically encoded Ca2+ indicator GCaMP2 (described above) while 
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melanoma cells were loaded with the synthetic Fluo-4 green fluorescent Ca2+ indicator. 
Before loading the cells with Fluo-4, they were washed twice with HBSS supplemented with 
2 mM CaCl2, 0.9 mM MgCl2 and 20 mM HEPES pH7.4. Then to the same solution 0.5 µM 
Fluo-4 AM (Molecular Probes, F14201) was added and cells were incubated for 30 min at RT. 
Following the incubation cells were washed twice with the same solution.  
Store operated Ca2+ entry was induced in two steps. First the intracellular Ca2+ stores were 
depleted. Cells were washed twice and kept in nominally Ca2+ free solution (HBSS 
supplemented with 100 µM EGTA, 100 µM CaCl2, 0.9 mM MgCl2 and 20 mM HEPES pH 7.4) 
and they were stimulated first by thapsigargin (2 µM) and after 2 minutes also by ATP (100 
µM). Than 3 minutes later store operated Ca2+ entry was induced by restoring the external 
Ca2+ concentration to 2 mM. Ca2+ signal was also evoked by the A23187 Ca2+ ionophore 
treatment. For this, cells were washed twice and kept in HBSS supplemented with 2 mM 
CaCl2, 0.9 mM MgCl2 and 20 mM HEPES pH7.4. Thereafter, 2 µM A23187 was added to the 
solution.  We used two different inhibitors, LaCl3 and Caloxin 1c2 to investigate the role of 
PMCA4b in the regulation of the intracellular Ca2+ signal. LaCl3 (1 mM) was administered 
when the Ca2+ signal reached its peak. The PMCA4b-specific inhibitor Caloxin 1c2 (20 µM) 
was added to the cells 10 minutes before the Ca2+ signal was triggered.  
Time-lapse images were acquired by Zeiss LSM500 and Olympus IX81 laser scanning confocal 
microscopes with a 60x (1.4) oil immersion objective. Z-resolution was adjusted to 1 µm and 
images were taken every 0.3 s/1 s. The relative fluorescence intensity values were calculated 
as F/Fo (where Fo was the average initial fluorescence). We used Fluoview FV500 (v4.1), 
ImageJ v1.42q and Prism4 v4.01 (GraphPad Software) software products to analyze the data. 
4.6 Protein analysis by Western Blot 
For total protein extraction cells were washed twice with PBS and then they were incubated 
with 6% TCA for 1-24 hours at 4 oC. The precipitated protein was centrifuged (4000g, 10 min, 
4oC) and the pellet was dissolved in a modified Laemmli-type sample buffer (62,5 mM Tris-
HCl, pH 6,8, 2% SDS, 10% glycerol, 5 mM EDTA, 100 mM DTT, 125 mg/ml urea és 0,28 mg/ml 
bromphenolblue). The protein concentration of the samples was determined with a 
modified Lowry method [147, 148]. 20-30 g proteins were loaded on 7.5% or 10% 
acrylamide gels and after electrophoresis samples were transferred to PVDF membranes. 
After blocking with 5% milk solution, the membranes were incubated with the appropriate 
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primary antibody. Primary antibodies are listed in Table 9.1. Anti-PMCA4b antibody, JA3 is 
specific for PMCA4b that recognizes the region between residues 1156-1180 [149]. As 
secondary antibodies, HRP-conjugated anti-rabbit and anti-mouse (Jackson 
ImmunoResearch, dilution 1:10000) were applied and Pierce ECL Western Blotting Substrate 
(Thermo Scientific) and luminography were used for detection. Densitometric analysis was 
performed by ImageJ software v1.42q. 
4.7 Immunofluorescence staining 
After washing twice with HBSS (37oC), cells were incubated in 4% paraformaldehyde solution 
at 37oC for 15 minutes. Then they were washed five times with PBS and to permeabilize the 
cell membrane, they were kept in ice cold methanol for 5 minutes. Cells were washed again 
five times with PBS and then they were kept in blocking buffer (PBS containing 2 mg/ml 
bovine serum albumin, 1% fish gelatin, 0.1% Triton-X 100, 5% goat serum) for 1 hour at RT. 
Subsequently primary antibody against PMCA4b (JA3, dilution 1:200) was applied in blocking 
buffer for 1 hour at RT. Next, cells were washed three times with PBS and they were 
incubated with the secondary antibody Alexa Flour 488-conjugated anti-mouse IgG 
(Invitrogen) in blocking buffer for 1 hour at RT. Images were acquired by Olympus IX-81 and 
Zeiss LSM500 laser scanning confocal microscopes with a 60x (1.4) oil immersion objective. 
Images were analyzed with FluoviewFV500 software v4.1 or ImageJ software v1.42q. 
4.8 Quantitative real-time reverse transcription PCR (qPCR) 
mRNA was isolated with TRIzol reagent (Life Technologies) from control, vemurafenib-
treated and HDAC inhibitor-treated melanoma cells. For reverse transcription the RevertAid 
Reverse Transcriptase (Thermo Scientific) was used and amplification was performed with 
the Maxima SYBR Green master mix (Thermo Scientific) on an Applied Biosystems® 7500 
Real-Time PCR System. All primer pairs used in the experiments are listed in Table 9.2 [150]. 
PMCA4b mRNA level was determined with the TaqMan assays Hs00608066_m1 (PMCA4b) 
and Hs99999905_m1 (GAPDH) (both from Thermo Scientific). 
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4.9 Proliferation assay 
Proliferation was analyzed by BrdU incorporation (colorimetric) assay (Roche Applied 
Science, Vienna, Austria, 11 647 229 001) according to the manufacturer’s protocol. A375-
GFP, A375-PMCA4bI and A375-PMCA4bII cells were seeded in triplicates on 96-well plates in 
1x104 cells/well concentration. Both control and vemurafenib-treated (48 hours) cells were 
labeled with 10 µM BrdU for 2 hours at 37oC. Incorporated BrdU level was determined by 
absorbance measurement at 370 nm (reference: 492 nm) and calculated as A370-A492. 
4.10 Viability assay 
Viability was tested on vemurafenib and HDAC inhibitor treated A375, A2058 and MEWO 
cells. First the cells were trypsinized and kept in suspension. Two dyes were mixed into the 
solution (Solution 13, Chemometec, 910-3013) from which Acridine Orange labeled all cells 
while DAPI stained only the non-viable cells. The number of cells in both populations was 
determined by the NucleoCounter NC-3000TM system (Chemometec) by applying 10 l of 
each sample on 8-well NC-slide. Viability was calculated as total cells - nonviable cells/total 
cells. 
4.11 Cell cycle analysis 
The ratio of vemurafenib and HDAC inhibitor treated A375, A2058 and MEWO cells in each 
cell cycle phases was analyzed based on their DNA content. First lysis buffer (Solution 10, 
910-3010, Chemometec) was mixed with DAPI stain solution (Solution 12, 910-3012, 
Chemometec) at a final concentration 10 g/ml DAPI. Then cells were trypsinized and 
incubated with the lysis buffer at 37oC. After five minutes reaction was stopped with 
stabilization buffer (Solution 11, 910-3011, Chemometec) and from each sample 10 l was 
added into 8-well NC-slide. Cellular fluorescence was measured with a NucleoCounter NC-
3000TM system (Chemometec).  
 4.12 Analysis of cellular morphology 
Morphological analysis of individual A375-GFP and A375-GFP-PMCA4b cells was performed 
on phase contrast images of the cells with the ImageJ 1.47v program´s particle analyzing 
option. We calculated the following morphological parameters: cellular area, aspect ratio 
36 
 
(defined as (major axis) / (minor axis) of the ellipse which best fits the shape of the cell) and 
circularity (defined as 4π* (cell area) / (cell perimeter)2). 
4.13 Cell migration assays 
Random and directional migration of melanoma cells was assessed with three different 
methodologies. 
4.13.1 Random migration assay using phase contrast videomicroscopy 
Migratory capacity of control and vemurafenib treated melanoma cells, as well as the A375-
GFP and the A375-GFP-PMCA4b cell lines were analyzed. Cells were plated in the inner 8 
wells of 24-well plates (Corning Incorporated, Corning, NY) and remained in the incubator 
overnight for cell attachment. At the beginning of videomicroscopic measurement, medium 
was changed to CO2-independent medium (Gibco-BRL Life Technologies, Carlsbad, CA) 
supplemented with FCS and 4 mM glutamine. Following the first 24-hour-measurement cell 
were treated with vemurafenib (0.5 µM) and followed for 72 hours afterwards. Cell 
migration was recorded by an inverted phase-contrast microscope (World Precision 
Instruments, Sarasota, FL) placed in a custom-built incubator maintaining 37°C and room 
ambient gas atmosphere. Images of 3 microscopic fields from each well were acquired every 
5 minutes. Cell positions were registered by a custom made cell-tracking program that 
enables manual labeling of individual cells [151]. Cell motility was calculated as the net 
displacement of cells between 0-12 and 48-60 hours of recordings with or without 
treatment.  
4.13.2 Random migration assay using fluorescent cell nuclei tracking assay 
A375 cells were treated with HDAC inhibitor valproate (4mM) for 48 hours. Before 
measurement cell nuclei were labeled with 0.1 μM Hoechst 33342 for 1 hour. Images were 
taken automatically by the ImageXpress Micro XL (Molecular Devices, Sunnyvale, CA USA) 
high content screening system with a Nikon CFI Super Plan Fluor ELWD ADM 10x objective. 
During the experiment cells were kept at 37oC in 5% CO2 humidified atmosphere. For 
Hoechst (447/60 nm) detection excitation wavelength was 377/50 nm. 4 images were 
acquired in every 30 minutes for 24 h. Data analysis was done with the Multidimensional 
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Motion Analysis module of MetaXpress High Content Image Acquisition & Analysis Software 
Version 5.3. The cell nuclei cut-off was 9–15 μm. 100 μm was adjusted as maximum 
displacement between two points on the trajectory of individual cells.  
4.13.3 Directional cell migration assay 
A375 cells were treated with various concentration of valproate for 48 hours and then cells 
were trypsinized and seeded on a 48-well Boyden chamber (Neuro probe, Gaithersburg, MD) 
with uncoated Nucleopore membranes (Whatman) at 2x104 cells/well concentration. Pore 
diameter of the membranes was 8 µm. Both in the upper and the bottom chamber DMEM 
containing 10% FCS was present and fibronectin (100 µg/ml, Millipore) was applied as a 
chemoattractant to the bottom chamber [152]. Cells were incubated for 6 hours at 37oC. 
Then from the upper side of the membrane the cells were removed by scraping and the filter 
was treated with methanol to fix the cells on the lower side. After staining the cells with 
toluidine blue, cells were counted with a light microscope at ×200 magnification. When the 
PMCA4 specific inhibitor caloxin 1c2 was used, it was added to the medium after seeding on 
the Boyden chamber at a 20 µM concentration. 
4.14 Lung colonization assay 
Tail vein injection of A375-GFP, A375-GFP-PMCA4b I and II cells (4x105cells/0.2 ml serum 
free DMEM) was performed on 11-week old female SCID mice (10 mice / group) provided by 
the National Institute of Oncology, Hungary. We sacrificed the mice 6 weeks later. The lung 
and the tumor tissue in the chest cavity were taken out, fixed in formalin and embedded in 
paraffin. Hematoxylin-eosin stained sections from the tissue blocks were analyzed with 
TissueFAXS System (TissueGnostics GmbH, Vienna, Austria) (20x). Using Tissue Quest 
program the tumor regions were highlighted and their area was quantified. The Guidelines 
for Animal Experiments were followed during the execution of the protocol and permission 
was obtained from the Department of Experimental Pharmacology in the National Institute 
of Oncology, Budapest, Hungary (permission number: 22.1/722/3/2010).  
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5. Results 
 
5.1 Distinct PMCA isoforms shape intracellular Ca2+ transients differently 
We wanted to analyze how differences in the kinetic properties of PMCA isoforms affected 
the patterns of Ca2+ transients. In our experiments we used three PMCA isoforms, PMCA4b, 
PMCA4a and PMCA2b, which strongly differed in their kinetics of activation by Ca2+-CaM and 
they also had distinct inactivation rates.  Previous experiments demonstrated that PMCA4b 
is activated by the Ca2+-CaM complex very slowly (kon) while the activation of PMCA2b and 
PMCA4a are much faster [42, 153, 154]. Based on these characteristics, PMCA4b is a “slow” 
pump, while PMCA2b and PMCA4a are “fast” pumps. Furthermore, PMCA4a has a fast Ca2+-
CaM off-rate (koff) which means it becomes quickly inactivated after a Ca
2+ spike. In contrast, 
PMCA4b and PMCA2b have a much slower Ca2+-CaM off-rates; they remain active longer, a 
characteristic called as the “memory” of the pumps [154]. 
We investigated the patterns of Ca2+ transients in response to either the store operated Ca2+ 
entry (SOCE) or after a Ca2+ ionophore stimulus. SOCE was induced by the addition of the 
SERCA pump inhibitor Thapsigargin (2 M) followed by ATP (100 M) in a nominally Ca2+ free 
solution. In this way the ER Ca2+ pool became depleted and its refill with Ca2+ was blocked. 
Then extracellular Ca2+ concentration (2 mM) was restored that resulted in a sharp increase 
in the intracellular Ca2+ concentration by allowing Ca2+ to enter the cells through store 
operated Ca2+ channels (SOCs). The SOCE-mediated Ca2+ signal lasted for about 10-15 
minutes depending on cell type and condition (Figure 3B).  
5.1.1 The effect of siRNA knockdown of PMCA4b on the SOCE mediated Ca2+ 
signal  
In our experimental model we used HeLa cells, which in a sub-confluent state express 
PMCA1 and PMCA4b in low levels but with confluency the expression of PMCA4b rises 
(Figure 3A). In order to investigate the role of PMCA4b in Ca2+ signaling, we stably 
downregulated PMC4b expression in HeLa cells with a PMCA4 specific short hairpin RNA. In 
this new cell line (sh-PMCA4) even in confluent state the abundance of PMCA4b remained 
very low (Figure 3A) while the expression of PMCA1 did not change.   
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Figure 3. SOCE-mediated Ca2+ signal in sh-PMCA4 and control Hela cells. (A) Analysis of 
PMCA1 and PMCA4 protein levels in 3, 5 or 7 days long grown control HeLa and sh-PMCA4 
cells. PMCA1 and PMCA4 protein expression level was analyzed by Western blotting using a 
pan-PMCA antibody 5F10 and a PMCA4b specific antibody JA3 to detect the two proteins. (B) 
A representative diagram of a SOCE mediated Ca2+ signal in sh-PMCA4 Hela cells. Addition of 
thapsigargin and ATP empties the ER Ca2+stores in nominally Ca2+-free solution then re-
addition of external Ca2+ (2 mM) induces SOCE. (C, D) cells were transfected with 
Ca2+indicator GCAMP2. Ca2+ signal was induced with Ca2+readdition in individual control 
HeLa (C) and sh-PMCA4 (D) cells. Each graph shows over 30 cells.  
To detect changes in the intracellular Ca2+ concentration cells were transiently transfected 
with the genetically encoded fluorescent Ca2+ indicator GCaMP2. We found that in all sh-
PMCA4 cells the decay of the Ca2+ transients was slow and nearly all cells responded equally 
to the incoming Ca2+ signal.  In contrast, in the control cells the pattern of Ca2+ signaling was 
more diverse; Ca2+ clearance was fast in a subpopulation of cells while in the rest of the cells 
the decay phase was similar to that of the sh-PMCA4b cells indicating that PMCA expression 
varies quite substantially between cells.  
40 
 
 5.1.2 The differential impact of slow and fast pumps with long or short 
memory on the SOCE mediated Ca2+ transients 
We generated mCherry-tagged PMCA4b, PMCA2b and PMCA4a constructs and co-
transfected HeLa cells with one of the PMCA isoforms and the Ca2+ indicator GCaMP2. This 
way we could follow changes in intracellular Ca2+ concentration and visualize PMCA 
expression in the same cell. In our experiments besides of the wild-type PMCA4b we also 
used the mutant PMCA4b-LA, in which three leucine residues (Leu1167-1169) were 
substituted with alanines in the pump´s C-terminal region. Earlier we characterized this 
mutant [45] and showed that it has an enhanced plasma membrane localization compared 
to the wild type protein while it retains all other characteristics of the wild type pump.  We 
found that overexpression of PMCA4b (slow pump with memory) strongly altered the shape 
of the Ca2+ transient (Figure 4A). 
 
Figure 4. SOCE mediated Ca2+ signals in PMCA4b, PMCA4b-LA, PMCA4a and PMCA2b 
expressing HeLa cells. Cells were co-transfected with mCherry-tagged PMCA constructs and 
Ca2+ indicator GCaMP2. The data in (A, B) shows results from > 15 cells. The graphs in (C) and 
(D) show the mean values of the Ca2+ signals from 20 to 30 cells ± 95% CI. 
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The first quick rise in the intracellular Ca2+ concentration was followed by a much faster 
decay phase than in the control HeLa or the sh-PMCA4 cells and this was followed by 
periodic baseline oscillations. Expression of PMCA4b-LA had a similar effect (Figure 4B) 
except that the baseline oscillations were far more synchronized in these cells presumably 
due to its higher abundance and more even distribution in the plasma membrane.  
Transient expression of PMCA4a (fast pump with no memory) had a very different effect on 
the Ca2+ transient. After a rapid increase, the intracellular Ca2+ concentration quickly 
decreased however it did not return to the baseline but stabilized in a new, increased 
steady-state level. Furthermore, cells expressing PMCA2b (fast pump with long memory) 
cleared very quickly the excess Ca2+ from the cytosol producing only one short peak.   
5.1.3 Influence of PMCA isoforms on Ca2+ transients generated independent of 
SOCE 
 In order to investigate the effect of different PMCA isoforms on the Ca2+ transients initiated 
by other stimuli, we induced Ca2+ transients with the calcium ionophore A23187 in the 
presence of 2 mM external Ca2+. The ionophore facilitates Ca2+ influx into the cells 
independently from plasma membrane channels. Interestingly, we found that PMCA 
isoforms influenced the ionophore-mediated intracellular Ca2+ transients in a similar manner 
as SOCE (Figure 5).  
 
Figure 5. Ca2+ transients after ionophore treatment in control, PMCA4b-LA, PMCA2b and 
PMCA4a expressing HeLa cells. Cells were transfected with Ca2+ indicator GCaMP2 and the 
indicated mCherry-tagged PMCA isoform. Ca2+ signal was initiated with A23187 (2 M). The 
data in (A, B) are results from > 15 cells. The graphs in (C) and (D) indicate the mean values of 
the Ca2+ signals from 20 to 30 cells ± 95% CI. 
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In control cells the pattern of the Ca2+ signals was diverse (Figure 5A), while in PMCA4b-LA 
expressing cells after an initial spike baseline oscillation developed (Figure 5B). Expression of 
fast responding pumps PMCA4a and PMCA2b initiated a quick response to the rise of the 
cytosolic Ca2+ concentration which resulted in a sustained elevation of the Ca2+ 
concentration or a rapid return to the basal level, respectively (Figure 5C). 
Our results showed for the first time that PMCA proteins play key role in the regulation of 
intracellular Ca2+ responses and can uniquely shape the incoming Ca2+ signal.  
 
5.2 The role of PMCA4b in the regulation of intracellular Ca2+ signaling in 
BRAF mutant melanoma cells 
Our results show that alterations in PMCA level and/or type can substantially change the 
Ca2+ signal that may further influence downstream events. Altered expression of PMCA 
proteins has already been described in several cancer types but not in metastatic melanoma 
[155]. In our study we used four melanoma cell lines: two BRAF (V600E) mutants (A375, 
A2058), one NRAS mutant (MZJZ) and one BRAF and NRAS wildtype (MEWO). First we 
analyzed which PMCA proteins are expressed in these cells and then we investigated the 
effects of mutant BRAF and MEK inhibitor treatments on PMCA expression and intracellular 
Ca2+ clearance.  
5.2.1 BRAF inhibitor treatment increases PMCA4b expression in BRAF mutant 
melanoma cells 
We used two mutant BRAF specific, low molecular weight inhibitors, vemurafenib (PLX4032) 
and GDC0879, which block the BRAF-MEK-ERK pathway selectively in BRAF (V600E) mutant 
cells. Cells were treated with 0.5 M Vemurafenib and 0.5 M GDC0879 for 72 hours and 
the expression of PMCA proteins was analyzed by Western blotting (Figure 6, 7).  
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Figure 6. Expression of PMCA4b is increased by BRAF inhibitor treatment selectively in 
melanoma cells with BRAF mutation. (A)Two BRAF wild type (MEWO, MJZJ) and two BRAF 
mutant (A2058, A375) cell lines were treated with mutant BRAF specific inhibitor 
vemurafenib (0.5 M) and GDC0879 (0.5 M) for 72 hours. Protein expression levels were 
determined by Western blot analysis. (B) After densitometric analysis PMCA4b protein levels 
were normalized to -tubulin expression and represented as fold increase over the untreated 
controls. Bars indicate means ± SE from three independent measurements. 
We investigated the expression of PMCA proteins with isoform specific antibodies and found 
that two PMCA isoforms, PMCA1 and PMCA4b were present in these cell lines (Figure 6A) 
while PMCA2 and PMCA3 were not detected (Figure 7).  We found that BRAF inhibitor 
treatment strongly increased the expression of PMCA4b selectively in BRAF mutant cells 
while it did not affect the expression of PMCA1 in any of these cells (Figure 6B). Hence in 
further experiments we concentrated on the changes of the PMCA4b protein.  
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Figure 7. Expression of different isoforms of PMCA3 and PMCA2 proteins were analyzed in 
control and vemurafenib treated MEWO, A375 and A2058 cells by Western blot. As markers 
we applied cell lysates from COS cells overexpressing the indicated PMCA isoforms. 
We examined the time course of PMCA4b expression at both the mRNA and protein levels in 
A375 cells.  
 
Figure 8. (A1) Changes in PMCA4b mRNA and (A2) protein expression after vemurafenib 
treatment (0.5 M) at different time points in A375 cells. (B1) A375 cells were treated with 
increasing amount of vemurafenib for 72 hours and expression of PMCA4b, SERCA2 and 
SERCA3, pERK and ERK was analyzed by western blots. (B2) Densitometric analysis of western 
blots of PMCA4b expression after concentration dependent treatment with vemurafenib in 
A375, MEWO and A2058 cells. Data are shown as fold increase over the untreated controls. 
Bars indicate means ± SE from three to five independent measurements. 
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A substantial increase in PMCA4b expression could be detected between 16 to 48 hours of 
treatment both at mRNA and protein levels (Figure 8A). After 48 hours PMCA4 mRNA 
expression declined to a lower level whereas protein abundance increased up to 72 hours 
and stayed constant at least for an additional 48 hours. Then we tested the effect of 
increasing concentration of vemurafenib on the abundance of PMCA4b (Figure 8B).   We 
found that 0.5 M vemurafenib concentration increased PMCA4b protein level almost 
maximally so we performed all further measurements with this concentration. 
We also analyzed the expression of sarco/endoplasmic reticulum Ca2+ ATPases, SERCA2 and 
SERCA3, after BRAF inhibitor treatment, both being important regulators of the intracellular 
Ca2+ homeostasis (Figure 8B2). SERCA3 was not detected in these cells while the expression 
of SERCA2 was abundant but did not change by the treatment. 
We also investigated the effect of vemurafenib treatment on the expression of various Ca2+ 
channels in the two BRAF mutant cell lines A375 and A2058 (Figure 9).  
 
 
Figure 9. Changes of mRNA expression level of Ca2+ channels after vemurafenib treatment 
(0.5 M, 72 hours). mRNA level of inositol 1,4,5-triphosphate receptor type 1-3 (IP3R1, IP3R2, 
IP3R3), Orai calcium release-activated calcium modulator 1 (Orai1), ryanodine receptor 2 
(RYR2), stromal interaction molecule 1 and 2 (STIM1, STIM2) and transient receptor potential 
cation channel subfamily M member 1 (TRPM1) was measured by quantitative real-time PCR 
analysis. mRNA levels were normalized to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression and bars show the means and SEM of two independent measurements 
implemented in duplicates. N.D., not detectable. C: control, V: vemurafenib. 
We found that the mRNA expression of the inositol 1,4,5-trisphosphate receptor type 1-3 
(IP3R1, IP3R2, IP3R3), Orai calcium release-activated calcium modulator 1 (Orai1), ryanodine 
receptor 2 (RYR2) and stromal interaction molecule 1 and 2 (STIM1, STIM2) was not 
modified by the treatment. Solely in A2058 cells the mRNA level of transient receptor 
46 
 
potential cation channel subfamily M member 1 (TRPM1) was substantially elevated while in 
A375 cells TRPM1 was not detectable neither before nor after the treatment. These results 
show that BRAF inhibitor treatment selectively upregulates the expression of the PMCA4b 
isoform in BRAF mutant melanoma cells. 
5.2.2 MEK inhibitor treatment increases PMCA4b expression in both BRAF 
mutant and NRAS mutant melanoma cells 
MEK1 and MEK2 kinases are part of the RAS/RAF/MEK/ERK pathway and since they are 
activated in both BRAF and NRAS mutant cells MEK inhibitors can be effective in both cell 
types. We treated one BRAF and NRAS wild type (MEWO), one NRAS mutant (MZJZ) and two 
BRAF mutant (A375, A2058) cell lines with a MEK1/2 inhibitor selumetinib (0.5 M AZD6244) 
for 72 hours and investigated its effect on PMCA4b expression (Figure 10).   
 
Figure 10. Effect of MEK inhibitor treatment on PMCA4b abundance. BRAF and NRAS wild 
type (MEWO), NRAS mutant (MZJZ) and BRAF mutant (A375, A2058) cell lines were 
incubated with MEK1/2 inhibitor selumetinib (0.5 M) for 72 hours.  (A) Protein level of 
PMCA4b, pERK and ERK was analyzed by western blots. (B) Densitometric analysis of 
PMCA4b protein levels was performed and data was normalized to -tubulin expression 
levels and expressed as fold increase over the untreated controls. Bars indicate means ± SE 
from three independent measurements. 
We found that selumetinib treatment on one hand increased PMCA4b abundance in both 
BRAF mutant cell lines comparably to BRAF inhibitor treatment, and on the other hand it had 
a similar effect in the NRAS mutant cells. This indicates that BRAF/MEK signaling plays a role 
in the regulation of PMCA4b expression.  
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5.2.3 PMCA4b upregulation is coupled with increased plasma membrane 
abundance 
In order to analyze the intracellular localization of PMCA4b before and after BRAF inhibitor 
treatment we performed immunofluorescent staining and confocal imaging. One BRAF wild 
type cell line (MEWO) and two BRAF mutant cell lines (A375, A2058) were treated with 0.5 
vemurafenib for 72 hours (Figure 11).  
 
Figure 11. Protein level of PMCA4b in the plasma membrane was analyzed after BRAF 
inhibitor treatment (0.5 M vemurafenib, 72 hours). Immunostaining with anti–PMCA4b 
antibody (JA3) was performed. Images were taken by confocal microscope with a 60X 
objective. 
We found that in the two BRAF mutant cell lines vemurafenib treatment strongly increased 
PMCA4b abundance in the plasma membrane. 
5.2.4 Increased PMCA4b expression results in enhanced Ca2+ clearance 
To investigate the effect of increased PMCA4b abundance on intracellular Ca2+ signaling we 
initiated intracellular Ca2+ signal in both control and vemurafenib treated cells and followed 
the changes of intracellular Ca2+ level in single cells with confocal microscopy. Cells were 
filled with Ca2+ indicator Fluo-4 and then SOCE mediated Ca2+ signal was induced in two 
steps. First external medium was changed to nominally Ca2+ free solution and  afterwards 2 
µM thapsigargin  and 100 µM ATP were added to the cells to deplete internal Ca2+ stores. 
Then the external Ca2+ concentration was restored to 2 mM and that evoked an intracellular 
Ca2+ increase (Figure 12).  
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Figure 12. SOCE mediated Ca2+ signal in control and vemurafenib treated melanoma cells. 
(A1, A2, B, C1) After pretreatment with vemurafenib (0.5 M, 48 hours) Ca2+ stores were 
depleted with Thapsigargin (2 M) and ATP (100 M) in nominally Ca2+-free environment, 
then extracellular Ca2+ concentration was restored (2 mM) which induced intracellular Ca2+  
increase by allowing Ca2+ entry through SOCE channels. Data show the average of normalized 
fluorescent intensity values (F/F0) of 10-30 cells from three independent measurements. (C2) 
Half peak decay time of the second phase of the SOCE signal in control and vemurafenib-
treated A375 cells was calculated. Bars represent the mean ± SD of individual cells analyzed 
in two to three independent experiments. Significances compared to control indicated by 
(***P<0.001); two-tailed unpaired t-test.  
 
We found that after vemurafenib treatment, intracellular Ca2+clearence was increased in the 
BRAF mutant cells (Figure 12B, C1) as compared to that of the control cells (Figure 12A1, A2). 
We also analyzed the changes of the intracellular Ca2+decay after a Ca2+ ionophore A23187 
stimulus that induced Ca2+uptake independent of the Ca2+entry channels. We found that 
under these conditions - similarly to that seen in case of SOCE - the peak decay half time was 
shorter in vemurafenib treated BRAF mutant cells as compared to that of the control cells 
(Figure 13A, C). 
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Figure 13. Ca2+signal in control and vemurafenib treated cells (0.5 M, 48 hours) after 
Ca2+ionophore stimulus. (A) A375 cells were treated with Vemurafenib (0.5 M) for 48 hours 
then stimulated with A23187 (2 M) in HBSS supplemented with 2 mM Ca2+. Where indicated 
lanthanum (LaCl3, 1 mM) was added right after when Ca
2+ signal reached the peak.  (B) Cell 
were pretreated with caloxin 1c2 for 10 minutes before Ca2+ signal was initiated with A23187 
in vemurafenib treated cells. (C) Half peak decay time of the Ca2+signal in control and 
vemurafenib-treated +/- caloxin 1c2 pretreated A375 cells was determined.  Data shows the 
average fluorescent intensity values of 10-15 cells. Bar graphs are mean ± SD of individual 
cells taken from two to three independent experiments. Significances are denoted by *** 
(P<0.001), ** (P<0.01); two-tailed unpaired t-test.  
 
To verify that PMCA4b is primarily responsible for the increased Ca2+decay, we performed 
the experiments in the presence of PMCA inhibitors lanthanum and a PMCA4-specific 
inhibitor caloxin1c2. Because lanthanum can also interfere with the function of 
Ca2+channels, LaCl3 was added right after the Ca
2+signal reached its peak. Immediately after 
addition lanthanum abolished Ca2+clearance and caused a sustained elevation of the 
cytosolic Ca2+ level (Figure 13A). Furthermore, PMCA4 specific inhibitor caloxin1c2 treatment 
also decreased Ca2+ clearance in the cells resulting in a slower decay phase similar to that 
seen in the control cells (Figure 13B, C). These two experiments show that an increased 
PMCA4b presence is coupled to an enhanced Ca2+ extrusion capacity and consequently 
faster Ca2+ clearance in vemurafenib treated BRAF mutant melanoma cells.   
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5.3 Elevated PMCA4b expression decreases the migratory capacity of A375 
cells 
Melanoma cells frequently show increased motility that can be coupled with strong 
metastatic capacity. Hence we analyzed how BRAF inhibitor treatment influenced the 
migratory capacity of the BRAF mutant cell lines (A375, A2058) and used the BRAF wild type 
cells (MEWO) as control. We performed time-lapse video microscopy to follow the 
movement of individual cells during the 3-day-long treatment period and the net migrated 
distance was analyzed (Figure 14A).  
 
Figure 14. Vemurafenib treatment strongly decreases the migratory capacity of BRAF mutant 
melanoma cells. Cells were treated with vemurafenib (0.5 M, 72 hours) and migration was 
recorded with time-lapse video microscopy. (A) Migration trajectories of 20 - 24 individual 
cells of control and vemurafenib treated A375 cells. The starting points of all trajectories 
were moved to the origin of the graph. (B) Bar graphs represent the mean +/- SEM of the net 
displacement of single cells during the first twelve hours of the treatment and between 48 – 
60 hours.  Significance was calculated between control and vemurafenib treated cells as 
(**P<0.01); two tailed Student’s t-test. 
We found that during the first twelve hours of the treatment vemurafenib moderately 
decreased the migration of A375 cells, while after two days cell migration was strongly 
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reduced by BRAF inhibition in both BRAF mutant cell lines (Figure 14B). The timing of the 
inhibitory effect on migration is corresponded with the increase in PMCA4b expression that 
was most substantial after 48 hours (Figure 8).  Migratory capacity of the BRAF wild type 
MEWO cells was found to be much lower compared to that of the BRAF mutant cells and this 
was not affected by the treatment, as expected.  
In order to investigate the effect of PMCA4b abundance on the migratory capacity of 
melanoma cells we stably transfected the BRAF mutant A375 and the BRAF wild type MEWO 
cell lines with GFP alone or with GFP-tagged PMCA4b. From A375 cells we established two 
PMCA4b expressing cell lines, independently; A375-GFP4b-I and A375-GFP4b-II (Figure 15A). 
Western blot analysis showed that the expression level of both the endogen and the GFP-
tagged PMCA4b were similar in both cells. Protein level of mutant BRAF (V600E) and pERK 
was not altered by the increased PMCA4b abundance. To verify that the GFP-tagged 
PMCA4b protein localizes properly, we took confocal images of the cells and found that in 
both cell types GFP-PMCA4b was present abundantly in the plasma membrane (Figure 15B). 
We also compared the proliferation rate among the original, the GFP-tagged and the two 
PMCA4b-expressing A375 cell lines and found that proliferation didn´t differ significantly 
among them. Treatment with vemurafenib strongly reduced cell division in all cell lines, as 
expected (Figure 15C).  
 
 
Figure 15. Generation of stably transfected GFP- and GFP-PMCA4b expressing A375 and 
MEWO cell lines. (A) Protein expression level of PMCA4b, BRAFV600E and pERK was 
determined by western blot. (B) Intracellular localization of GFP-PMCA4b was analyzed by 
confocal imaging (60X objective, scale bar, 20 m). (C) Proliferation was measured by BrdU 
incorporation assay. Data indicate the mean +/- SEM of three independent experiments. 
Significances refer to differences between control and vemurafenib treated cells (*P<0.05; 
* P<0.01); two tailed Student’s t-test. 
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However, when we analyzed the migratory capacity of the GFP and the GFP-PMCA4b 
expressing cells, we found a strong decrease in the motility of both A375-GFP-4b expressing 
cell lines compared to the control GFP expressing cells (Figure 16). The motility of the 
MEWO-GFP-4b cells was identical to the control GFP expressing MEWO cells.  
 
 
Figure 16. GFP-PMCA4b expressing A375 cells show decreased migration compared to 
control. Cell migration was recorded by time-lapse video microscopy for 16 hours. (A) 
Trajectories show the movement of individual cells. Their initial positions were transferred to 
the origin of the plot. (B) Net displacement in 12 hours was determined. Significances 
indicate the differences between GFP-expressing control and GFP-PMCA4b expressing cells 
(**P<0.01, ***P<0.001); two-tailed unpaired t-test.    
Furthermore, the morphology of the PMCA4b expressing cells was also strongly altered. 
While the control cells had an elongated shape with more long outgrowths, the PMCA4b 
overexpressing cells were more epithelial like with a rounded, cobble-stone shape (Figure 
17A). We analyzed several morphological parameters of the cells and found that A375-GFP-
4b cells show increased circularity and cellular area compared with A375-GFP cells while 
their aspect ratio (defined as (major axis) / (minor axis)) was decreased (Figure 17B).  
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Figure 17. A375-GFP-PMCA4b cells show altered cellular morphology. (A) Cell masks were 
generated from phase contrast video microscopy images with ImageJ program to highlight 
cell shape differences. (B) Quantitative analysis of cellular area, aspect ratio ((major axis) / 
(minor axis)) and circularity was performed in both GFP expressing (n=249) and GFP-PMCA4b 
expressing (n=204) cells. Bars demonstrate means ± SEM from 3 independent experiments. 
Significant differences compared to GFP expressing cells was analyzed (*** (P<0.001); two-
tailed unpaired t-test). 
Since PMCA4b overexpression shifted the cellular morphology of the cells toward a more 
epithelial-like form, we analyzed the mRNA expression of several proteins involved in the 
epithelial mesenchymal transition process. However, we found no differences in the 
expression of ZEB-1, Snail and vimentin between the GFP and GFP-PMCA4b expressing cells 
and E-cadherin was not present in either of these cell lines (Figure 18A).  
 
Figure 18. (A) Relative mRNA expression of EMT marker proteins E-cadherin, ZEB-1, Snail and 
vimentin was determined by quantitative real-time PCR in A375-GFP-PMCA4b and A375-GFP 
cells. N.D. stands for not detectable. (B) Analysis of SERCA2 protein expression with western 
blot in vemurafenib treated (48 hours, 0.5 M) and control A375-GFP-PMCA4b and A375-GFP 
cell lines. 
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We also compared the expression of the ER Ca2+ pump SERCA2 in the GFP and the two GFP-
PMCA4b expressing cell lines and found that it was not modified (Figure 18B).  
These results show that overexpression of PMCA4b strongly decreases the migratory 
capacity of A375 cells and this effect is coupled with an altered cellular morphology. 
Vemurafenib had a similar effect on the migration of both BRAF mutant melanoma cell lines 
but BRAF inhibition also decreased the proliferation of the cells while PMCA4b 
overexpression did not.  
5.4 PMCA4b expressing A375 cells have decreased metastatic capacity in vivo 
Melanoma patients with metastasis have a particularly grim prognosis. Cell migration is a 
critical step in metastatic spread therefore, we analyzed the effect of increased PMCA4b 
presence in A375 cells on their invasive capacity. We performed a lung colonization assay in 
mice during which 4x104 A375-GFP or A375-GFP-PMCA4b cells/mouse were injected into the 
animal´s tail vein. After 6 weeks mice were sacrificed and their lung tissues were analyzed. 
We found that in the control group tumor cells established large tumors in the lung 
parenchyma and some tumor cells invaded the lung tissue along blood vessels or bronchioles 
(Figure 19A). While in the two groups of animals injected with PMCA4b expressing cells, only 
smaller tumors were formed on the surface or in the connective tissue of the lung. 
Quantification showed that PMCA4b overexpression strongly decreased the number of 
animals with tumor in their lungs (Figure 19B). Furthermore, the tumor burden - measured 
as total tumor area in the cross sections of lungs - was also reduced in the PMCA4b 
expressing group (Figure 19C). 
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Figure 19. Lung colonization assay in mice to compare the metastatic activity of A375-GFP 
and A375-GFP-PMCA4b cells. 4x104 cells / mouse (n=10) were injected. (A) Tumors could be 
readily identified with hematoxylin staining in paraffin tissue sections. In the representative 
images white asterisks mark tumors in the lung parenchyma, black asterisks indicate tumors 
in the connective tissue. Black frames circumscribe the high-magnification areas of the lower 
panels. Black arrows point to areas where along blood vessels and bronchiole invasive tumor 
cells are noticeable. Arrowheads mark interlobular tumors. (B) The number of animals with 
tumor in the lung was significantly higher in the control group compared with A375-GFP-
PMCA4b cells receiving two groups (Chi-square test, P=0.034). (C) Total area of tumors was 
quantified on hematoxylin-stained tissue sections in each group. 
In order to investigate if PMCA4b expression is decreased during the malignant 
transformation of melanomas, two ONCOMINE data sets with benign nevi and melanoma 
samples were analyzed (Figure 20). We found that the number of cases with low PMCA4 
expression was higher in cutaneous melanomas in both data sets. Furthermore, combination 
of the data from the two data sets showed that high expression of PMCA4 was present only 
in 26 melanoma samples out of 69 (38%), while in benign nevi that was the case in 21 
samples out of 27 (77%). 
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Figure 20. PMCA4b expression in benign nevi and melanoma specimens based on gene 
expression microarray data from ONCOMINE platform. (A, B) Two independent gene 
expression microarray dataset were used. (C) The data from the two cohorts were combined 
which showed that cases with low PMCA4b expression were significantly more in the 
cutaneous melanoma group than in in the benign nevus group (p=0.0006). 
Altogether, our results show that BRAF inhibition selectively upregulates PMCA4b expression 
in BRAF mutant melanoma cells which results in an increased Ca2+ clearance after 
stimulation. Furthermore, both BRAF inhibition and PMCA4b overexpression decreased the 
migration capacity of the BRAF mutant A375 cells and PMCA4b overexpression also reduced 
the cells´ metastatic capacity in vivo. Interestingly, despite its strong anti-migratory effect 
PMCA4b expression did not alter the proliferation of the cells that is a typical feature of the 
metastasis suppressor genes. 
 
5.5 The effect of HDAC inhibitor treatment alone and in combination with 
vemurafenib on PMCA protein expression in melanoma cells 
The impact of histone deacetylase treatment on the expression of the PMCA4b has already 
been investigated in breast and colon cancer cell lines [93, 94]. In these studies both short 
chain fatty acids such as butyrate and valproic acid and the hydroxamic acid SAHA 
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(vorinostat) increased the expression. However, the effect of HDAC inhibitor treatment on 
PMCA expression in melanoma cells was not formerly investigated.  
5.5.1 HDAC inhibitor treatment increases the abundance of both the PMCA4b 
and the PMCA1 isoforms in melanoma cells  
First we treated three melanoma cell lines, the BRAF wild type (MEWO) and the two BRAF 
mutant (A375, A2058) cells, with an increasing concentration of SAHA or valproate, and 
analyzed the changes in PMCA expression by Western blot (Figure 21). We used two 
different antibodies against the PMCA proteins, a PMCA4 isoform specific one (JA9) and a 
pan-PMCA antibody (5F10). The latter recognized two bands in all cell lines from which the 
lower band corresponded to PMCA4b while the upper band to PMCA1, as determined by the 
isoform specific antibodies JA9 and NR1, respectively (Figure 21A). We found that PMCA4b 
expression was strongly elevated in both MEWO and A375 cells while only moderately in 
A2058 cells in response to the HDAC inhibitor treatments.  
 
Figure 21. Concentration dependent treatment of melanoma cells with HDAC inhibitor SAHA 
and valproate. After 48 hours total cell lysates were prepared and analyzed by Western 
Blotting (30 g / sample). C: control, D: DMSO. Densitometric analysis of PMCA4b expression 
was performed than data were normalized to -tubulin expression level and were presented 
as fold increase over untreated control. Diagrams show the means ± SE from three 
independent measurements. Significance was calculated by ANOVA and Dunett`s post hoc 
tests and asterisks show differences (* p < 0.05) from control.  
 
Surprisingly, beside the increased PMCA4b expression the abundance of PMCA1 was also 
increased by the treatment of the A375 and A2058 cells. Expression of both isoforms was 
already elevated after 0.5 M SAHA and 1 mM valproate treatment (Figure 21B). 
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Then we analyzed the changes in PMCA expression at different time points of the treatment 
(Figure 22) and found that PMCA4b level reached saturation after 48 hours in all cell lines. 
PMCA4b expression also went up in the control samples at later time points as the culture 
reached confluency in good accordance with earlier findings [45]. 
 
Figure 22. Time dependent change of PMCA proteins during HDAC inhibitor treatment. Cells 
were treated with 2 M SAHA or 2 mM valproate for the indicated time points. PMCA protein 
expression was analyzed with Western Blotting. Densitometric analysis of PMCA4b 
expression was performed than data were normalized to -tubulin expression level and were 
presented as fold increase over untreated control. Diagrams show the means ± SE from three 
independent experiments. Significance was calculated by ANOVA and Dunett`s post hoc tests 
and asterisks show differences (* p < 0.05) from control.   
 
Since our experiments showed that BRAF inhibitor treatment induced PMCA4b expression in 
the BRAF mutant melanoma cell lines, we wanted to test the combined effect of BRAF and 
HDAC inhibition on the PMCA abundance. Therefore, we treated all three cell lines either 
with 1 M SAHA or 2 mM valproate in combination with 0.5 M vemurafenib (Figure 23). 
Interestingly, we found no additive effect of the two treatments on PMCA4b expression in 
these cell lines. In A375 cells BRAF inhibitor treatment had a stronger effect than the HDAC 
inhibitors, while in A2058 cells all treatment increased PMCA4b expression in a similar 
extent (Figure 23B). In BRAF wild type MEWO cells only HDAC inhibitors had an effect on 
PMCA4 abundance, as expected.  
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Figure 23. Combination treatment with HDAC inhibitor SAHA or valproate with BRAF inhibitor 
vemurafenib had no additive effect on PMCA4b protein expression. Treatment was 
performed with 1 M SAHA or 2 mM valproate in combination with 0.5 M vemurafenib for 
48 hours. (A) Expressions of proteins were determined with Western Blotting and analyzed 
with densitometry. PMCA4b and PMCA1 were detected with isoform specific and pan-PMCA 
antibodies as well. (B, C, D) Data were normalized to -tubulin expression levels and 
expressed as fold increase over untreated controls. Diagrams show the means ± SE from 
three independent experiments. Asterisks represents significant differences compared to 
control (* p < 0.05) by two-tailed paired t-test.  
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As we have shown earlier, vemurafenib treatment does not influence PMCA1 abundance 
and combined treatment had no additional effect above HDAC inhibitor treatment alone, as 
expected. We also analyzed the changes in ERK phosphorylation and found that contrary to 
vemurafenib treatment HDAC inhibition did not decrease ERK activation but eventually even 
slightly increased that (Figure 23C). This shows that the effect of HDAC inhibitors on PMCA 
expression is independent of ERK activation in these cell lines. Furthermore, this effect was 
also independent from the BRAF mutational status of the cells, since HDAC inhibitors 
increased PMCA4b expression in both BRAF wild type (MEWO) and BRAF mutant (A375, 
A2058) cell lines. Additionally, we analyzed the changes in acetylation of the H3 histone 
protein after HDAC inhibitor and vemurafenib treatment (Figure 24). We found that 
treatment with the HDAC inhibitors – in contrast to the BRAF inhibitors - increased H3 
histone acetylation in all cell lines. 
 
Figure 24. Alternations in H3 histone acetylation following the treatment with HDAC inhibitor 
SAHA and valproate or BRAF inhibitor vemurafenib for 48 hours. Vem: 0.5 M vemurafenib, V 
+ S: 0.5 M vemurafenib and 1 M SAHA, V + V: 0.5 M vemurafenib and 2 mM valproate. 
Acetylated-H3 protein level was determined by Western blot and the data were 
densitometrically analyzed, normalized to -tubulin expression levels and expressed as fold 
change compared to control.  
Intracellular Ca2+ signals are shaped by the concerted action of Ca2+ channels and pumps in 
the plasma membrane and the ER. It has been shown that treatment with HDAC inhibitors 
can alter the expression of the Ca2+-signaling molecules [27, 156, 157] hence we analyzed 
the changes in the expression of SERCA2 and SERCA3 proteins after HDAC inhibitor 
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treatment alone or in combination with vemurafenib (Figure 24). The housekeeping isoform 
SERCA2 - which was detected in all three cell lines - was slightly decreased by the treatment 
in the two BRAF mutant cells (Figure 24D). It has been demonstrated that SERCA3 expression 
is increased during cancer cell differentiation [27, 156]. We found that HDAC inhibitor 
treatment evoked SERCA3 expression only in A2058 cells while SERCA3 could not be 
detected in the other two cell lines with or without treatment. We also investigated the 
changes in the expression of the Ca2+ channels at the mRNA level in response to 2 mM 
valproate alone or in combination with 0.5 M vemurafenib (Figure 25).  
 
Figure 25. Alternations in the mRNA expression of Ca2+ channels and PMCA4b after 
treatment with valproate alone (2 mM) or in combination with vemurafenib (0.5 M) for 48 
hours. The mRNA level of inositol 1,4,5-triphosphate receptor type 1-3 (IP3R1, IP3R2, IP3R3), 
stromal interaction molecule 1 and 2 (STIM1, STIM2), Orai calcium release-activated calcium 
modulator 1 (Orai1), transient receptor potential cation channel subfamily M member 1 
(TRPM1) and PMCA4b was determined with quantitative real-time PCR analysis. Data was 
normalized to the expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Bars show means ± S.E.M. of three independent measurements done in duplicates. N.D. 
stands for not detectable.  
Importantly, in MEWO and A375 cells the mRNA expression of these channels was not 
influenced by the treatments. In the A2058 cell line IP3R3 mRNA level was strongly increased 
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after valproate treatment while the combination treatment triggered TRPM1 expression. We 
showed earlier that vemurafenib treatment caused an increase in TRPM1 mRNA level that 
could be responsible for this latter effect. We also demonstrated that the mRNA level of 
PMCA4b changed in a similar manner as protein expression after HDAC inhibitor treatment.  
5.5.2 HDAC inhibitor treatment increases Ca2+ clearance in a PMCA4b 
dependent manner 
Next we studied if the increase in PMCA4b expression affected intracellular Ca2+ clearance. 
In order to study this, we analyzed the intracellular localization of PMCA4b before and after 
HDAC inhibitor treatment.  We found that treatment with either valproate (2 mM) or SAHA 
(1 M) induced an increase in the abundance of PMCA4b in the plasma membrane of the 
cells (Figure 26), indicating that the newly generated pump was functional. 
 
Figure 26. Immunofluorescence staining of PMCA4b in control and HDAC inhibitor treated 
cells. SAHA (1 M) and valproate (2 mM) treatment was applied for 48 hours. 
Immunofluorescence staining was performed with anti-PMCA4b antibody. Confocal 
microscopy (60x objective) was used for staining analysis. 
Then, A375 cells were filled with the Ca2+-sensitive fluorescent indicator Fluo-4 and the 
intracellular Ca2+ signal was measured in both control and HDAC inhibitor treated cells after 
stimulation with the Ca2+ ionophore A23187. We found that in the valproate treated cells the 
decay of the Ca2+ signal was faster than in the control cells (Figure 27A). In order to 
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investigate the specific role of PMCA4b in the faster decline of the fluorescent signal we 
repeated the signal measurement after pretreating the cells with the PMCA4-specific 
inhibitor caloxin 1C2 (20 M) (Figure 27B, C). Importantly, we found that the inhibitor 
treatment was able to significantly reverse the increase in Ca2+ decay underlining the 
importance of PMCA4b in shaping the Ca2+ signal.  
 
Figure 27. The effect of HDAC inhibitor treatment on Ca2+ clearance is PMCA4 dependent. 
A375 cells were treated with valproate (2 mM) for 48 hours than they were filled with Ca2+-
sensitive fluorescent indicator Fluo-4. (A) Intracellular Ca2+ signal was induced with Ca2+ 
ionophore, A23187 (2 M) in control and valproate treated cells. (B) Valproate treated cells 
were first pretreated with caloxin 1c2 (20 M) PMCA4-specific peptide inhibitor for 10 
minutes before ionophore stimulation. (C) Analysis of the half-peak decay time in control, 
valproate treated and valproate and caloxin 1c2 treated A375 cells. Bars represent mean ± 
SD of individual cells coming from three independent measurements. Significance was 
calculated between control and valproate-treated cells or valproate and valproate plus 
caloxin treated cells by two tailed unpaired t-test (*** P<0.001). 
5.5.3 Changes in cell viability and cell cycle progression after HDAC inhibitor 
treatment in melanoma cells 
Since earlier it was found that HDAC inhibitor treatment could influence the viability of 
cancer cells [107], we analyzed how HDAC inhibitor treatment alone or in combination with 
vemurafenib influenced cell viability and cell cycle progression in MEWO, A375 and A2058 
cells. To calculate viability we measured the number of dead cells and the total number of 
the cells. While in MEWO and A2058 cells viability was not influenced by any of the 
treatments, in A375 cells vemurafenib alone and in combination with both HDAC inhibitors 
had a small, but significant decreasing effect (Figure 28 A1, B1, C1).   
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Figure 28. Cell cycle progression and cell viability was assessed after SAHA and valproate 
treatment alone or in combination with vemurafenib. Experiments were performed for 48 
hours. For single treatments vemurafenib (0.5 M), SAHA (1 M), valproate (2 or 4 mM) 
were used, in combination V+S: vemurafenib (0.5 M) + SAHA (1 M), V+V: vemurafenib (0.5 
M) + valproate (2 mM) were applied. (A1, B, C1) Viability was calculated as total cells - 
nonviable cells/total cells. (A, B, C) Ratio of cells in cell cycle phases Sub G1 and G2/M. Data 
represents the mean of three independent experiments. Significance was calculated 
compared to control indicated by asterisks (* p < 0.05); two-tailed paired t-test. 
In order to analyze the impact of the inhibitors on cell cycle progression, we determined the 
ratio of cells among four cell cycle phases based on their DNA content. Dying cells are in the 
Sub G1 phase, resting cells in the G0/G1 phase, during DNA synthesis the cells are in the S 
phase followed by the G2/M phase where cells have two sets of paired chromosomes. We 
found that all three cell lines were affected differently by the treatment. In MEWO cells 
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neither proliferation nor cell death were changed by any of the treatments (Figure 28 A2, 
A3). In A375 cells, in good accordance with our earlier results, cell division was strongly 
inhibited by vemurafenib, however, it was not influenced by the HDAC inhibitors. In 
contrast, cell death was increased by all of the treatments and combination of vemurafenib 
with valproate had an additive effect compared to single treatments (Figure 28 B2, B3). In 
A2058 cells, cell death was slightly increased by HDAC inhibitor treatment but not by 
vemurafenib. Proliferation was decreased among the single agents mostly by SAHA, while 
among combination treatments valproate together with vemurafenib had the strongest 
effect (Figure 28 B3, C3). Altogether, we found that both the viability and proliferation were 
only moderately affected by HDAC inhibitor treatments in melanoma cells and this effect 
was slightly increased by the combination treatments in the BRAF mutant cell lines. 
5.5.4 Valproate treatment inhibits both random and directed migration of A375 
cells 
Earlier we showed that vemurafenib increased PMCA4b expression and decreased cell 
migration of A375 cells. Moreover, PMCA4b overexpression mimicked the effect of 
vemurafenib on cell motility. Since valproate treatment increased PMCA4b expression in this 
cell line in a similar extent as vemurafenib did, we wanted to investigate its effect on the 
migratory capacity of the cells. First we compared random cell migration between control 
and valproate treated cells for 24 hours with an automated fluorescence microscope 
(ImageXpress Micro XL). We found that valproate treatment strongly reduced the velocity of 
the cells as compared to that of the control cells (Figure 30A). We also tested the effect of 
valproate treatment on the directed migration of A375 cells with modified Boyden chamber 
assay, where a fibronectin coat was applied in the lower chamber as chemoattractant. After 
48 hours pretreatment with an increasing concentration of valproate, cells were added to 
the chambers. Following a 6-hour incubation period the number of cells on the lower side of 
the Boyden chamber membrane was assessed. We found that 1 mM valproate treatment 
decreased significantly the directional movement of the cells that was further reduced with 
increasing concentrations of the drug (Figure 30B1). 
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Figure 30. Both random and directed migration of A375 cells are strongly decreased by 
valproate treatment. (A) Mean velocity was measured during random migration for 24 hours 
after 4 mM valproate treatment with an automated fluorescence microscope (ImageXpress 
Micro XL). Data represents the mean ± SEM of ≥ 100 individual cells from three independent 
experiments. Significance relative to control is indicated by (*** P<0.001); two-tailed 
unpaired t-test. (B1) Directed migration was analyzed with modified Boyden chamber assay 
for 6 hours after treatment with valproate in the indicated concentrations. The number of 
cells in representative fields on the lower side of the Boyden chamber membrane was 
counted. (B2) Cells were treated with 4 mM valproate for 48 hours, than caloxin 1c2 (20 nM) 
was added to the cells before the modified Boyden chamber assay. Data shows the mean of 
three experiments ± SEM. Significances are indicated by (*** P<0.001); two-tailed unpaired t-
test. 
To investigate the specific role of PMCA4b in this effect, we performed the same assay as 
before but in the presence of the PMCA4b specific inhibitor caloxin 1c2. Interestingly, caloxin 
treatment increased the directed migration of both control and vaproate treated cells 
(Figure 30B2) suggesting that PMCA4b played an important role in the regulation of the 
migration of A375 cells. 
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6. Discussion 
 
The PMCA (ATP2B1-4) family of proteins shows great diversity counting more than 20 
distinct variants. While their biochemical properties and some specific cellular functions 
have been determined, less was known about their specific role in shaping the Ca2+ signal. 
Therefore, we generated a methodology to test the influence of PMCAs on the Ca2+ 
transients in HeLa cells. Later the same methodology was used to study the role of PMCAs in 
different kinds of cancer cells, including cell lines of melanoma origin. Recent studies have 
shown that PMCA4b is downregulated in certain type of cancers. Here we found that 
inhibition of the BRAF/MEK/ERK pathway in BRAF mutant melanoma cells increased the 
expression of PMCA4b, and resulted in enhanced Ca2+ clearance and decreased cell 
migration. Similarly, when PMCA expression was induced by HDAC inhibitor treatment 
independently from the ERK activation, a faster Ca2+ clearance rate and reduced migratory 
capacity was evoked in melanoma cells.  Furthermore, specific inhibitors of PMCA4 could 
partially reverse these effects proving that PMCA4 has a primary role in the regulation of 
Ca2+ signaling and cell migration.  
6.1 The effect of PMCA activity on the SOCE induced Ca2+ signal 
It was suggested earlier that PMCA played an important role in the regulation of the decay 
phase of the Ca2+ signal induced by the store operated or other means of Ca2+ entry into the 
cytosol. After a rise in the intracellular Ca2+ level besides the PMCAs also the SERCA proteins, 
the mitochondria and when present the Na+/Ca2+ exchangers can remove Ca2+ from the 
cytosol. The specific effects of each transporter were tested by the use of specific inhibitors. 
Klishin et al. [158] used calf pulmonary endothelial cells;  they depleted the internal Ca2+ 
stores by the addition of thapsigargin in a Ca2+ free medium and then Ca2+ entry was 
initiated by increasing the extracellular Ca2+ concentration. They found that in these cells 
PMCA shaped primarily the decay phase of the Ca2+ signal while the Na+/Ca2+ exchange 
affected mostly the size of the peak, and mitochondria had no effect.  
The role of the PMCA in the regulation of the Ca2+ signal decay phase was also demonstrated 
in immune cells [159]. Interestingly, after activation of Jurkat T-cells with lectin 
phytohemagglutinin (PHA) a decrease in Ca2+ clearance was found. It was shown that both 
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PMCA and ER Ca2+ sensor protein STIM1 translocate to the forming immunological synapse 
(IS) and STIM1 attenuates PMCA activity by direct binding. Later it was found that another 
protein partner of STIM1 (POST) was also required to the decreased activity of PMCA in the 
IS [65]. Upon store depletion POST binds to STIM1 and this complex interacts with PMCA, 
which results in a decreased Ca2+ extrusion capacity of the pump.  
It was shown that PMCAs can also influence intracellular Ca2+ signaling by controlling the 
availability of PIP2. On the one hand, it can decrease PLC activity by removing Ca
2+ from its 
vicinity and on the other PMCA can directly bind PIP2 molecules preventing their processing 
to IP3. In this way PMCAs regulate Ca
2+ release from the ER by a mechanism independent of 
its Ca2+ transporting ability [44]. 
In our experiments we demonstrated that PMCA isoforms due to their distinct kinetic 
features influence the pattern of the Ca2+ signal initiated by SOCE differently. PMCA2b is a 
fast pump with long memory [154] and its expression resulted in a short Ca2+ spike. Because 
this isoform remains active for about 20 minutes after stimulation - even when Ca2+ level 
decreases - it precludes the formation of another immediate Ca2+ signal. Its ability to 
generate distinct Ca2+ spikes is particularly important in the Purkinje neurons in the 
cerebellum [160, 161]. The activation kinetics of PMCA2 makes it possible to react fast Ca2+ 
signals quickly in the nerves system where it is abundantly present. The length of the Ca2+ 
signal also influences the activation of downstream Ca2+ dependent signaling molecules. 
PMCA2 overexpression was shown to decrease the activation of transcription factor NFAT in 
HEK cells by decreasing the activity of Ca2+- dependent phosphatase calcineurin [62].  
PMCA4a and PMCA4b are the C-terminal splice variants of the same protein but they 
strongly differ in their kinetic properties and consequently in their tissue distribution. 
PMCA4a can get activated quickly but then it has a short memory [41]. It is expressed in 
smooth muscles, in the heart, in the nervous system and it is the only PMCA form that is 
present in the sperm tail. In sperms a sperm-specific cation channel (CatSper) was described 
that necessary for sperm hyperactivation [162]. Absence of PMCA4 in mice results in male 
infertility due to impaired sperm motility [163].  Interestingly, in activated sperm cells the 
pattern of the Ca2+ signal is similar to that observed in PMCA4a expressing Hela cells [164]. 
PMCA4b is a slow pump with long memory [41, 154] and so it is capable to regulate Ca2+ 
signals in non-excitable cells. We found that in PMCA4b expressing cells, store operated Ca2+ 
entry evoked first a large peak followed by periodic baseline oscillations. In non-excitable 
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cells, Ca2+ oscillations are mostly described as repetitive Ca2+ release and uptake from the ER 
to the cytosol regulated by the IP3R ER receptor channels and the ER Ca
2+ pumps SERCA 
proteins [165]. In our experimental setup, we excluded the effect of the ER by first inducing 
Ca2+ release in zero Ca2+ environment and by blocking SERCA activity with thapsigargin. 
Under these conditions, Ca2+ oscillations were produced by the concerted action of SOCE 
channels and PMCA4b. Ca2+ oscillations can greatly vary in their spatial and temporal 
features and oscillatory signals with distinct frequency and amplitude were shown to initiate 
different downstream cellular responses [6]. Previously it was demonstrated in human bone 
marrow-derived mesenchymal stem cells that PMCA can play a role in the regulation of Ca2+ 
oscillations [166].  It was also found that increased presence of PMCA4 resulted in decreased 
activation of the transcription factor NFAT in both HEK and endothelial cells [61, 64].  
Furthermore, a mathematical model was generated by our group that took into account the 
activation kinetics of the PMCA isoforms and their distinct Ca2+ -CaM binding. The 
mathematical model described well our experimental results. According to the model, the 
slow activation of PMCA4b was necessary to the formation of Ca2+ oscillations. SOCE 
channels became activated quickly and hence Ca2+ concentration increased substantially 
before PMCA4b was fully active. 
6.2 The role of PMCA4b in the regulation of melanoma cell migration 
In migrating cells an increasing Ca2+ gradient is present from the front towards the rear of 
the cells [82]. It was found in endothelial cells that there is an increased abundance of PMCA 
in the front of the cells [87]. It was demonstrated that this increased presence of the PMCA 
contributed to the maintenance of the low Ca2+ level and to the formation of local Ca2+ 
pulses and periodic activation of the MLCK resulting in pulsatile retraction and adhesion in 
the front. It was also found that ectopic expression of PMCA4 in VEGF treated endothelial 
cells decreased NFAT activity and migratory capacity of the cells [64]. However the role of 
PMCAs in cancer cell migration has not been yet investigated. 
Melanoma cells often have strong migratory and metastatic capacity and it was 
demonstrated that increased Ca2+ uptake contributes to this phenomena. It was found that 
SOCE channel OraI1 and its partner STIM2 are strongly expressed in melanoma cells, and in 
the invasive edge of primary tumors and lymph node metastases [134]. Downregulation of 
their expression decreased the migratory and metastatic capacity of the cells but enhanced 
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their proliferation. In another study STIM1 and Orai1 was found to be abundantly present in 
melanoma cell lines and tissues and their inhibition decreased both the proliferation and 
migration of the cells [135]. SOCE activation was associated with ERK activation which could 
be reversed by CaMKII or Raf1 inhibition. Furthermore, STIM1 and ORAI1 induced Ca2+ 
oscillations were shown to initiate invadopodium formation and extracellular matrix 
degradation [136] through the regulation of Src kinase activity and MT1-MMP release. It was 
also demonstrated that STIM1 and Orai1 expression was higher in melanoma cell lines than 
in normal epidermal human melanocytes and their expression was increased in cells derived 
from metastatic melanoma compared to cells derived from primary melanoma. 
Downregulation of STIM1 decreased the metastatic capacity of melanoma cells in vivo in a 
lung colonization assay.  
Expression of several TRPM channels (TRPM8, TRPM2, TRPM7) was also found to be 
upregulated in melanoma cells and to have an increasing effect on proliferation [132]. These 
data suggest that increased Ca2+ uptake play a major a role in the strong proliferative and 
metastatic capacity of melanoma cells. 
In our work we found that in BRAF mutant melanoma cells inhibition of the BRAF/MEK/ERK 
pathway induced PMCA4 expression and that was coupled with enhanced Ca2+ clearance and 
decreased migratory capacity of the cells. The expression of PMCA4b alone was able to 
strongly reduce the motility and metastatic capacity of A375 melanoma cells in vivo. 
Microarray data showed that PMCA4b expression was lower in melanoma specimens than in 
benign nevi. Our data are in good accordance with the above described results on Ca2+ 
channels. Ca2+ uptake is elevated by synergistic actions of the upregulated Ca2+ channels and 
downregulated Ca2+ release mechanisms resulting in increased migratory and metastatic 
activity of melanoma cells. Since we demonstrated that PMCA activity can influence the 
SOCE mediated Ca2+ signal it is possible that PMCA reduces melanoma cell motility by 
opposing the Ca2+ entry by SOCs, especially because we found no change in the expression of 
store operated Ca2+ channels (Orai1, STIM1 and 2) and inositol 1,4,5-trisphosphate receptors 
type 1-3 (IP3R1, IP3R2, IP3R3) after BRAF inhibitor treatment, or in the PMCA4b expressing 
cells.  
We demonstrated that increased PMCA4b expression strongly reduced the metastatic 
capacity of A375 cells. However, we found that it did not influence the proliferation of the 
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cells. In conclusion, PMCA4b reduces the ability of melanoma cells to metastasize without 
affecting proliferation fulfilling the definition of metastasis suppressors [167].  
6.3 The effect of HDAC inhibitor treatment on PMCA expression and cell 
migration in melanoma cells 
It was found previously that HDAC inhibitor treatment increased the expression of PMCA4 in 
colon and breast cancer cells. Treatment with short chain fatty acids and trichostatin A 
evoked a marked increase in the expression of PMCA4b and a moderate elevation of 
PMCA1b protein level in various gastric and colon cancer cell lines [93]. In MCF-7 breast 
cancer cells, both short chain fatty acid and SAHA treatments induced a strong upregulation 
in PMCA4b expression and that was coupled with an enhanced Ca2+ clearance from the cells 
[94]. It was also demonstrated that PMCA4 is present in a substantial amount in the normal 
breast tissue.  
We found a similar pattern of PMCA expression in melanoma cells in response to HDAC 
inhibitor treatments. Both valproate and SAHA increased the expression of PMCA4b in 
melanoma cell lines independent of their BRAF mutational status. Interestingly, HDAC 
inhibitor treatments also induced the expression of PMCA1 in two out of the three 
melanoma cell lines. We showed that increased PMCA4b abundance resulted in enhanced 
Ca2+ clearance in the A375 cells and their motility was also strongly decreased by valproate 
treatment. Both effects were partially reverted by the use of PMCA4 specific inhibitor 
caloxin 1c2 proving that PMCA4b play a primary role in regulation of the intracellular Ca2+ 
signal and cell migration. Importantly, we found no change in the expression of the SOCE 
channels by the treatments suggesting that they are not responsible for the decreased 
motility of the HDACi treated cells. 
We found that HDACis enhanced the abundance of PMCA1 in the BRAF mutant A375 and 
A2058 cells but it did not change that of in the BRAF wild type MEWO cell line. Previously, it 
was shown that the expression of PMCA1 was moderately altered by HDAC inhibitors in 
colon cancer cells while it was not modified in MCF-7 breast cancer cells [93, 94]. It was 
demonstrated that PMCA1 expression is regulated by vitamin D in osteoblasts, the small 
intestine, kidney distal tubules and also in colon cancer cells [168, 169]. Deletion of PMCA1 
specifically in the intestinal absorptive cells caused decreased responsiveness to 1, 25-
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dihydroxyvitamin D3 and reduced bone mineral density in mice [170]. In melanoma cell 
lines, the antiproliferative effect of 1, 25(OH)2D3 was shown to be cell line dependent [171], 
however, lower vitamin D levels in the blood of melanoma patients were associated with 
advanced melanoma stage [172]. Since Vitamin D can influence HDAC activity [173] it is 
possible that vitamin D regulate PMCA1 expression through epigenetic mechanisms.  
We also tested the effect of HDAC inhibitors alone or in combination with vemurafenib on 
the viability of melanoma cells. It was found previously that treatment with HDAC inhibitors 
can induce apoptosis in melanoma cells, however, this effect was strongly cell line and 
inhibitor dependent [113]. We found that the viability of these cell lines was not 
substantially altered by any of the treatments. We also analyzed the ratio of the proliferative 
and apoptotic cells after treatments and found that the changes were cell type specific. 
Proliferation of A375 cells was strongly reduced by BRAF inhibition but it was not affected by 
the HDAC inhibitor treatment. The ratio of cells in the SubG1 phase was increased by both 
treatments and it was further increased by the combination treatment with vemurafenib 
and valproate. The PTEN mutant A2058 cell line showed a moderate response to 
vemurafenib treatment but HDAC inhibitor could decrease proliferation and increase cell 
death significantly in these cells. Similar results were obtained on cell viability by other 
groups as well [174] and a higher ratio of apoptotic cells was observed only at higher 
concentration of HDACis [115]. 
Taken together, our data show that PMCA proteins play an important role in the regulation 
of the intracellular Ca2+ signal. BRAF inhibitor treatment selectively upregulated the 
expression of the PMCA4b isoform only in BRAF mutant melanoma cells, while HDAC 
inhibitor treatment increased PMCA4b abundance in all cell lines independent of their BRAF 
mutational status. Increased PMCA4b expression enhanced intracellular Ca2+ clearance and 
decreased the migratory and metastatic capacity of the highly motile A375 melanoma cells. 
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7. Summary 
Plasma membrane calcium ATPases (PMCA) maintain the resting low intracellular calcium 
concentration by pumping out excess calcium from the cytosol. There are four different 
PMCA proteins (PMCA1-4) coded by four genes and through alternative splicing more than 
20 isoforms are produced. PMCA isoforms differ in their kinetic properties, tissue 
distribution and in their intracellular localization. Regarding their activation by Ca2+-
calmodulin PMCAs can be categorized as fast or slow pumps. Depending on their inactivation 
rates PMCAs with short and long lasting activity can be distinguished that is referred as to 
the memory from earlier Ca2+ spikes.  
We found that PMCA isoforms due to their distinct kinetic features influence the pattern of 
the Ca2+ signal initiated by SOCE differently and this is in good accordance with their 
physiological role in specific cell types and tissues. In our measurements, the quickly 
activating PMCA2b with long memory produced distinct Ca2+ spikes just like the spikes in the 
Purkinje neurons in the cerebellum. PMCA4a is also a fast pump but with a short memory. As 
a result, after a fast decay the intracellular Ca2+ concentration stabilized in a new, increased 
steady-state level in the PMCA4a expressing cells. Earlier a similar pattern was found also in 
activated sperm cells. The PMCA4b isoform is primarily present in non-excitable cells, we 
found that its slower activation rate allows the formation of relatively large Ca2+ transients 
and can initiate periodic baseline oscillations. 
Earlier it was demonstrated that expression of PMCA proteins can be altered in colon and 
breast cancer cells. We found that inhibition of the BRAF/MEK/ERK pathway selectively 
upregulated the expression of PMCA4b in BRAF mutant melanoma cells and this effect was 
coupled with enhanced Ca2+ clearance in the cells. Expression of PMCA4b in BRAF mutant 
A375 cells profoundly changed the morphology of the cells, decreased their migratory 
capacity in vitro and reduced their metastatic capacity in vivo. Furthermore, histone 
deacetylase inhibitor treatment increased PMCA4b expression in melanoma cells 
independent from ERK activation and it enhanced the Ca2+ clearance and decreased the 
motility of the cells in a PMCA4b dependent manner.  Our data demonstrates for the first 
time that PMCA4b is an important regulator of the migration of melanoma cells and that 
PMCA4b is a putative metastasis suppressor protein. 
74 
 
8. Összefoglalás 
A plazmamembrán típusú kalcium ATPázok (PMCA) részt vesznek a nyugalmi kalcium 
koncentráció fenntartásában. A négy PMCA fehérje (PMCA1-4) négy különböző génen 
kódolt, melyekről alternatív “splicing” során több mint húsz izoforma képződhet. Az 
izoformák különböznek kinetikai tulajdonságaikban, szöveti megoszlásukban és sejten belüli 
elhelyezkedésükben.   
Úgy találtuk, hogy az egyes PMCA fehérjék eltérő kinetikai tulajdonságainak köszönhetően 
különbözőképpen befolyásolják a Ca2+ szignál mintázatát, ami összhangban áll fiziológiás 
szerepükkel az egyes sejttípusokban. A Ca2+/kalmodulin komplex által gyorsan aktiválódó, de 
hosszan aktívan maradó, hosszú memóriájú PMCA2b hatására egyedi Ca2+ tüskék alakultak ki 
kísérleteinkben csak úgy, mint a Purkinje sejtekben, a kisagyban. A PMCA4a variáns szintén 
gyorsan aktiválódik, azonban az aktivitását gyorsan elveszíti. Ennek következtében a 
PMCA4a-t kifejező sejtekben a kezdeti gyors csökkenés után egy új, megemelkedett 
intracelluláris Ca2+ szint alakult ki, amihez hasonló mintázatot találtak aktivált 
spermiumokban is. A PMCA4b elsősorban nem-ingerelhető sejtekben van jelen, amelyekben 
lassú aktivációja hozzájárul a relatíve nagyobb amplitudójú és hosszabb ideig fenntartott Ca2+ 
jelek és az azt követő periodikus alapszintű oszcilláció kialakulásához. 
Korábbi eredmények alapján a PMCA fehérjék kifejeződése megváltozik vastagbél es emlő 
tumor sejtekben a normál szövethez képest. Kísérleteinkben azt tapasztaltuk, hogy BRAF 
mutáns melanóma sejtekben a BRAF/MEK/ERK jelátvitel gátlásakor a PMCA4b szintje 
megemelkedett és ezzel összhangban a sejtet érő stimulust követően a Ca2+ eltávolítás 
sebessége megnőtt. A PMCA4b túltermeltetése BRAF mutáns A375 sejtekben a sejtalak 
drasztikus változását okozta, valamint in vitro a sejtek mozgását, in vivo pedig az 
áttétképzést csökkentette. Úgy találtuk, hogy a PMCA4b fehérje kifejeződése hiszton 
deacetiláz gátló kezelés hatására is megemelkedett a melanóma sejtekben, de ez a hatás 
független volt az ERK fehérje aktivációjától. Ugyanakkor ezekre a sejtekre is fokozott Ca2+ 
eltávolítás és csökkent migráció volt a jellemző, PMCA4b függő módon.  
Eredményeink azt mutatják, hogy a PMCA4b fontos szerepet játszik a sejtek Ca2+ jelátviteli 
folyamataiban és feltehetően ezen keresztül a melanóma sejtek mozgásának 
szabályozásában.  Végül érdemes kiemelni, hogy a PMCA4b fehérjét elsőként azonosítottuk, 
mint lehetséges metasztázis szuppresszort.   
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9. Tables and abbreviations 
9.1 Primary antibodies 
Name Source Type Dilution 
Anti-PMCA4b (JA3) [149] Mouse monoclonal 1:1000 
Anti-PMCA1 Affinity BioReagents, PA1-914 Rabbit polyclonal 1:1000 
Anti-PMCA2 [175] Rabbit polyclonal 1:1500 
Anti-PMCA3 [175]   
Anti-pan-PMCA (5F10) [175] Mouse monoclonal 1:5000 
Anti-SERCA2 Sigma-Aldrich, S1439 Mouse monoclonal 1:2500 
Anti-SERCA3 (PL/IM430) [93] Mouse monoclonal 1:200 
Anti-phospho- 
p44/42MAPK (ERK1/2) 
Cell Signaling, CST4370S Rabbit monoclonal 1:1000 
Anti-ERK1/2 (MK1) Santa Cruz, sc135900 Mouse monoclonal 1:500 
Anti--tubulin Abcam, ab6046 Rabbit polyclonal 1:1000 
Anti-BRAF-V600E (VE1) Spring Bioscience Corp.  
E19290 
Mouse monoclonal 1:500 
Anti-acetyl-Histone H3 
(Lys 9/Lys 14) 
Cell Signaling, 9677 Rabbit polyclonal 1:1000 
Anti-Na+/K+ ATPase Enzo Life Sciences 
BML-SA247-0100 
Mouse monoclonal 1:2000 
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9.2 Primers used for SYBR Green expression analysis 
Oligo Name Sequence (5'-3') 
IP3R1 forward  TTG GGC CTG GTT GAT GAT CG 
IP3R1 reverse  TTT GGG CAG AGT AGC GGT TC 
IP3R2 forward  AGA AGA ATG CCA TGC GTG TG 
IP3R2 reverse  ACC CTC GCT TCT CAG TTT CC 
IP3R3 forward  CCT AAG AAG TTC CGT GAC TG 
IP3R3 reverse  TCC TTG TCC TGC TTA GTC TG 
ORAI1 forward  TGG ACG CTG ACC ACG ACT AC 
ORAI1 reverse  CCT CGA TGT TGG GCA GGA TG 
RYR2 forward  ATG TAT CTG TGC TGC CTG TC 
RYR2 reverse  CTT CTG ATC GCT GCT TAG AG 
STIM1 forward  GAT GGA CGA TGA TGC CAA TG 
STIM1 reverse  GAA GGT GCT GTG TTT CAC TG 
STIM2 forward  AAC GAC ACT TCC CAG GAT AG 
STIM2 reverse  ACC ACA TCC AAT GCC TTG AG 
TRPM1 forward  GTG TCA GCA CAG GTG TTA TC 
TRPM1 reverse  TCC TTT CCA ACC AGG TCT TC 
E-cadherin forward CAGAGCCTCTGGATAGAGAACGCA 
E-cadherin reverse GGCATTGTAGGTGTTCACATCATCGTC 
SNAIL1 forward TATGCTGCCTTCCCAGGCTTG 
SNAIL1 reverse ATGTGCATCTTGAGGGCACCC 
ZEB1 forward CCAGTGGTCATGATGAAAATGGAACACC 
ZEB1 reverse CAGACTGCGTCACATGTCTTTGATCTC 
Vimentin forward GGCTCAGATTCAGGAACAGC 
Vimentin reverse CTGAATCTCATCCTGCAGGC 
GAPDH forward AGCTCACTGGCATGGCCTTC 
GAPDH reverse ACGCCTGCTTCACCACCTTC 
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9.3 Abbreviations 
AA: arachidonic acid 
AE: adverse effect 
APC: antigen presenting cell 
ATP: adenosine triphosphate 
CaM: calmodulin 
CaMKII: Ca2+/calmodulin-dependent protein kinase II 
CaN: calcineurin 
CBS: calmodulin binding sequence 
CDK: cyclin dependent kinase 
CICR: Ca2+ induced Ca2+ release 
COX-2: cyclooxygenase-2 
CRAC: calcium release activated calcium current 
CTLA-4: cytotoxic T-lymphocyte-associated antigen 4 
DAG: diacyglycerol 
DAPI: 4´,6-diamidino-2-fenilindol 
DAPK: death-associated protein kinase 
DTT: dithiothreitol 
ECM: extracellular matrix 
EGF: epidermal growth factor 
eNOS: endothelial nitric oxide synthase 
Epac: exchange protein directly activated by cyclic AMP 
ER: endoplasmic reticulum 
ERK: extracellular-signal regulated kinase 
FA: focal adhesion 
FAK: focal adhesion kinase 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
GCaMP2: GFP-based Ca2+ probe 
GFP: green fluorescent protein 
GPCR: G-protein-coupled receptor 
HAT: histone acetyl transferase 
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HBSS: Hanks´ Balanced Salt Solution 
HDAC: histone deacetylase 
HGF: hepatocyte growth factor 
HUVEC: human umbilical vein endothelial cell 
IGF: insulin like growth factor 
IP3: inositol 1,4,5-trisphosphate 
IP3R: inositol 1,4,5-trisphosphate receptor 
IS: immunological synapse 
MAGE: melanoma-associated antigen 
MAGUK: membrane-associated guanylate kinase 
MAPK: mitogen activated protein kinase 
MCU: mitochondrial calcium uniporter 
MEK: MAPK/ERK kinase 
MLCK: myosin light chain kinase 
MMP: matrix metalloproteinase 
mTOR: mechanistic target of rapamycin 
NCX: Na+/Ca2+ exchanger 
NFAT: nuclear factor of activated T-cell 
NHERF2: Na+/H+ exchanger regulatory factor 2 
NMDA: N-methyl-D-aspartate 
nNOS: neural nitric oxide synthase 
PD1: programmed cell death receptor 1 
PD-L1: programmed death-ligand 1 
PIP2: phosphatidylinositol-4,5- bisphosphate 
PIP3: phosphatidylinositol-3,4,5- bisphosphate 
PLC: phospholipase C 
PMCA: plasma membrane Ca2+ ATPases 
POST: partner of STIM 
PSD-95: post synaptic density protein 95  
PTEN: phosphatase and tensin homolog 
PTP: permeability transition pore 
RAF: rapidly accelerated fibrosarcoma 
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RAS: rat sarcoma 
RASSF1: Ras association domain-containing protein 1 
ROS: reactive oxygen species 
RTKR: receptor tyrosine kinase-linked receptor 
RYR: ryanodine receptor 
SAHA: suberoylanilide hyroxamic acid 
SERCA: sarco/endoplasmic reticulum Ca2+ ATPases 
SOC: store operated Ca2+ channel 
SOCE: store operated Ca2+ entry 
SPCA: secretory-pathway Ca2+ ATPase 
SR: sarcoplasmic reticulum 
STIM: stromal interacting molecule 
TCA: trichloroacetic acid 
TGF: transforming growth factor 
TRPC: transient receptor potential cation channel subfamily C (“C” for canonical) 
TRPM: transient receptor potential cation channel subfamily M (“M” for melastatin) 
TRPV: transient receptor potential cation channel subfamily V (“M” for vanilloid) 
TSA: trichostatin A 
VEGF: vascular endothelial growth factor 
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